Non-CB1/CB2 Molecular Targets of Cannabinoids: TRP Channels, PPARs, GPRs, Serotonin, and NaV Channels

Why cannabinoid science cannot be reduced to CB1 and CB2

The shorthand version of cannabinoid pharmacology says this: THC acts at CB1, immune effects run through CB2, and everything else is a footnote. That framing is easy to teach and easy to repeat. It is also wrong often enough to block serious understanding of pain, inflammation, anxiety, itch, nausea, metabolism, and neuroprotection.

CB1 and CB2 matter. CB1 is abundant in the brain and explains much of THC’s intoxication, memory disruption, appetite effects, and part of its analgesia. CB2 is central to many immune and inflammatory discussions. But cannabinoids are not tidy ligands built for one receptor each. They are lipophilic, shape-flexible molecules that interact with a wider pharmacological field: transient receptor potential channels such as TRPV1 and TRPA1, nuclear receptors such as PPAR-gamma, orphan or still-debated cannabinoid-adjacent GPCRs such as GPR55 and GPR18, serotonin receptors including 5-HT1A, adenosine-related signaling, fatty acid transport and metabolism, and, in newer work, voltage-gated sodium channels including NaV1.7 and NaV1.8.

That wider field matters because mechanism determines risk and benefit. Regulators are already confronting this problem in adjacent drug-policy fights. In 2025, the U.S. Department of Health and Human Services said that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” when backing DEA action on enhanced 7-OH products. The specific compound is not a cannabinoid, but the policy lesson travels well: once chemists start modifying natural-product scaffolds and concentrating metabolites, simple source-based categories stop protecting the public. A molecule’s target profile matters more than whether popular writing treats it as familiar.

The receptor myth in popular cannabis writing

Popular cannabis explainers usually present receptors as on-off switches: THC turns CB1 on, CBD does not “bind strongly,” therefore CBD must be weak or mysterious. That account collapses several distinct pharmacological ideas into one vague verb, bind.

Orthosteric agonism is the classic case. A ligand occupies the receptor’s main active site and stabilizes signaling. THC is a partial agonist at CB1 and CB2. That is one kind of action, not the template for all cannabinoid biology. A compound can instead act allosterically, changing how another ligand works at the receptor without occupying the same site. It can open, sensitize, or desensitize an ion channel. It can enter the cell and activate a nuclear receptor that changes gene transcription over hours rather than milliseconds. It can inhibit a transporter, alter membrane properties, or slow an enzyme that degrades an endogenous signaling lipid.

CBD is the clearest rebuttal to receptor reductionism. Its approved clinical use is not based on CB1 agonism. The FDA label for cannabidiol oral solution states that it is indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year of age and older. Whatever full mechanism underlies that effect, it is not adequately explained by the old story that meaningful cannabinoid action equals strong CB1 or CB2 activation. Mechanistic candidates repeatedly raised in the literature include TRPV1, 5-HT1A-related signaling, adenosine modulation, intracellular calcium effects, and enzyme or transporter interactions. None can be treated as the sole answer, but together they show why the simplistic receptor myth fails.

History also points the same way. Raphael Mechoulam’s endocannabinoid work opened a field centered on anandamide and 2-AG, yet even anandamide is not merely a CB1 ligand. It also activates TRPV1, the heat and capsaicin receptor whose broader sensory importance was recognized in the 2021 Nobel Prize to David Julius and Ardem Patapoutian for discoveries of receptors for temperature and touch. Once an endogenous cannabinoid can signal through both a GPCR and a TRP channel, the “CB1/CB2 only” model is no longer a model. It is a cartoon.

Polypharmacology: one ligand, many targets

A better starting point is polypharmacology. One ligand, many targets, with different affinities, efficacies, tissues, and consequences. In pharmacology, “dirty” is sometimes used pejoratively, but for cannabinoids it is often simply descriptive.

Consider how many action types sit under the same umbrella term. THC is a CB1/CB2 partial agonist, yet 2025 work highlighted by Hebrew University reported that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 nociceptive sodium channels. That is not receptor agonism at all. It is ion-channel inhibition at targets already viewed as prime pain-drug candidates. If that line of work holds up across species and dosing conditions, part of THC analgesia may come from a mechanism that looks more like a local excitability brake than a classic cannabinoid-receptor effect.

CBD shows a different style of promiscuity. Across assay systems it has been reported to influence TRPV1, TRPA1, TRPM8, 5-HT1A, PPAR-gamma, GPR55, and adenosine tone, among others. The problem is not lack of mechanisms. The problem is sorting which mechanisms matter at clinically reached concentrations in humans. In vitro target engagement is cheap. Translating it is hard. A micromolar effect in an overexpressing cell line does not automatically explain patient outcomes after oral dosing, first-pass metabolism, protein binding, and tissue partitioning.

Other phytocannabinoids complicate the picture further. CBG has been discussed as an alpha-2 adrenergic, TRP-active, and 5-HT1A-interacting compound in some systems. CBC has been linked to TRPA1 and TRPV channels. THCV can behave differently from delta-9-THC at CB1 depending on dose and context, while also carrying non-CB1 possibilities. Acidic cannabinoids such as CBDA and THCA raise additional questions because decarboxylation, stability, and metabolite formation all alter target exposure. The same bottle label can therefore hide very different pharmacology once route, heat, metabolism, and formulation enter the story.

Even within GPCR pharmacology, the field has moved past crude labels. GPR55 is still sometimes called a “CB3” candidate, but that remains disputed for good reason; the signaling, ligand set, and physiological role do not map neatly onto the classical cannabinoid receptors. GPR18 and GPR119 are also discussed in cannabinoid-adjacent literature, especially around inflammation, metabolism, and gut signaling, but the evidence is uneven. Medicinal chemists know this. A 2016 Journal of Medicinal Chemistry paper, “Library Docking for Cannabinoid-2 Receptor Ligands,” captured a structure-based approach that is almost the opposite of popular receptor lore: target-selective design, docking, scaffold optimization, and intentional separation of desired effects from unwanted ones. The field is not asking “does it hit cannabinoid receptors?” It is asking which targets, in what state, in what tissue, at what concentration, and with what bias.

Why non-CB1/CB2 targets matter clinically

This is where the science stops being semantic and starts affecting medicine.

For pain, non-CB1 targets may be the most plausible route to useful drugs with less intoxication. TRPV1, TRPA1, peripheral sodium channels, and inflammatory transcription pathways all offer ways to reduce nociceptor firing or neuroimmune sensitization without strong central CB1 activation. A 2026 ScienceDaily report on a cannabis compound that “relieves pain without the high” is only a research-stage signal, not a finished clinical answer, but the direction makes sense. If analgesia can be pushed toward peripheral ion channels or restricted tissue exposure, the old tradeoff between pain relief and psychoactive burden may soften.

For inflammation and metabolism, PPAR-gamma is a good example of why receptor categories matter. PPARs are nuclear receptors, not membrane cannabinoid receptors. Activation changes gene-expression programs involved in lipid handling, insulin sensitivity, and inflammatory tone. Some cannabinoid effects reported in metabolic or inflammatory models fit this slower transcriptional biology better than they fit rapid CB1 signaling. But again, concentration and intracellular access matter. A paper showing PPAR activation in a reporter assay does not prove a clinically relevant anti-inflammatory effect in humans.

For anxiety and nausea, serotonin-linked mechanisms keep resurfacing, especially 5-HT1A. The data are mixed and often indirect, but the persistence of the signal is telling. CBD’s anxiolytic reputation is hard to map onto CB1/CB2 alone. That is one reason companies are trying to engineer differentiated cannabinoid-inspired compounds rather than simply making stronger THC analogues. In 2025, MIRA Pharmaceuticals reported preclinical data claiming that its candidate MIRA-55 showed a “differentiated mechanism of action” and “anxiolytic activity relative to THC.” Company press releases are low-tier evidence and should be treated that way. Still, they reveal where drug development is headed: away from the idea that the best cannabinoid medicine is just cleaner CB1 stimulation.

Itch, migraine, epilepsy, bowel disorders, and neuroprotection all sit in the same mechanistic zone. TRP channels regulate sensory gain. GPRs may shape immune and epithelial signaling. PPARs alter inflammatory programs. Sodium channels control excitability directly. Serotonin pathways influence anxiety, emesis, and stress responses. Once these systems are placed next to CB1 and CB2 rather than beneath them, many real-world cannabinoid effects look less mysterious and more pharmacologically ordinary.

The oversimplified model survives because it is easy. The better model survives contact with data.

The endocannabinoid system versus the broader cannabinoid target landscape

Popular cannabis writing often treats pharmacology as a two-receptor story: CB1 explains psychoactive effects, CB2 explains immune effects, and everything else is detail. That framing is too small for the evidence. It misses why cannabidiol cannot be explained cleanly by CB1 or CB2, why some cannabinoids trigger burning or analgesia through TRP channels, why intracellular nuclear receptors such as PPAR-γ keep appearing in inflammation studies, and why even THC itself can affect pain-relevant sodium channels outside classical cannabinoid signaling. If the field wants to explain pain, anxiety, inflammation, seizure control, or safety problems with novel intoxicants, receptor reductionism has to go.

The regulatory moment makes that plain. In 2025, HHS stated that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” while backing scheduling action against enhanced 7-OH products. That statement was not about cannabis, but it captures the same pharmacological lesson: once manufacturers move from familiar plant constituents to enhanced, semi-synthetic, or structurally modified intoxicants, simple category labels stop being useful. “THC-like” tells you far less than target profile, potency, metabolites, tissue distribution, and off-target activity.

Canonical targets: CB1, CB2, anandamide, and 2-AG

The canonical endocannabinoid system still matters. CB1 and CB2 are G protein-coupled receptors, mainly Gi/o-coupled, identified in the late 20th century and mapped in detail by researchers including Ken Mackie and Vincenzo Di Marzo. CB1 is heavily expressed in the central nervous system, especially in cortex, hippocampus, basal ganglia, and cerebellum, which is why THC’s partial agonism there is linked to intoxication, memory effects, altered motor control, and appetite changes. CB2 is enriched in immune cells and peripheral tissues, though not absent from the brain. Activation of either receptor usually reduces cAMP formation, modulates ion channels, and changes transmitter release.

The endogenous ligands are anandamide and 2-arachidonoylglycerol, usually shortened to anandamide and 2-AG. Raphael Mechoulam’s group was central to this history: anandamide was identified in 1992, 2-AG soon after. They are not stored in synaptic vesicles like classical neurotransmitters. They are synthesized on demand from membrane lipid precursors and often act retrogradely, moving from postsynaptic cells back to presynaptic terminals to dampen neurotransmitter release. Anandamide is degraded mainly by FAAH; 2-AG mainly by MAGL. That biochemical cycle is the backbone of the endocannabinoid system.

But the backbone is not the whole skeleton. Anandamide is also a TRPV1 agonist. CBD has low direct affinity for CB1 and CB2 compared with THC yet clearly has clinically meaningful actions; the FDA-approved oral cannabidiol solution is indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year and older. That approved use is a standing reminder that clinically relevant cannabinoid effects do not have to line up with strong CB1 agonism.

What counts as a cannabinoid target

A practical definition is better than a purist one. A cannabinoid target is any molecular site at which a phytocannabinoid, endocannabinoid, metabolite, or cannabinoid-inspired scaffold binds or functionally modulates signaling at concentrations that could matter in cells, tissues, animals, or humans. By that standard, the landscape broadens fast.

TRP channels are the most familiar non-CB examples. TRPV1, TRPA1, TRPV2, and TRPM8 recur across cannabinoid papers. This is not a side note. David Julius and Ardem Patapoutian shared the 2021 Nobel Prize in Physiology or Medicine “for their discoveries of receptors for temperature and touch,” a reminder that ion channels governing heat, cold, irritation, and mechanosensation sit directly in pain pathways. Anandamide activates TRPV1. CBD, CBG, CBC, and acidic cannabinoids have all shown TRP activity in vitro, often with concentration-sensitive, sometimes biphasic effects. A cannabinoid that first activates TRPV1 can later desensitize it, producing the paradox of initial irritation followed by analgesia.

PPARs widen the frame further. PPAR-α and PPAR-γ are nuclear receptors that regulate transcription related to lipid metabolism and inflammation. Some cannabinoids and endocannabinoid-related lipids act here directly or after intracellular accumulation and metabolism. These are slower, gene-regulatory effects, not the millisecond signaling of CB1. That matters for chronic inflammation claims, which often make more sense through nuclear signaling than through acute synaptic cannabinoid receptor activity.

Then there are the orphan or still-debated GPCRs, especially GPR55, GPR18, and GPR119. GPR55 has repeatedly been proposed as a “CB3” candidate, and the label remains premature. The receptor is real; the classification is disputed. CBD is often described as a GPR55 antagonist or negative modulator in experimental systems, while certain endogenous lipids and synthetic ligands can activate it. GPR18 and GPR119 come up in inflammation, metabolism, and immune signaling, but the evidence is uneven and species effects can be substantial.

Serotonin receptors, especially 5-HT1A, also belong in this broader map. CBD’s anxiolytic and antiemetic literature often implicates 5-HT1A, though direct agonism versus indirect facilitation is still argued over. That distinction matters. A compound that weakly binds a receptor but reliably shifts circuit behavior through allosteric or network mechanisms may still have meaningful effects in vivo. The same caution applies to company-reported preclinical programs: in 2025, MIRA Pharmaceuticals said its candidate MIRA-55 had a “differentiated mechanism of action” and showed anxiolytic activity relative to THC. That is not confirmation of clinical benefit, but it shows where medicinal chemistry is heading—away from blunt THC mimicry and toward target-shaped cannabinoid pharmacology.

Sodium channels deserve a place here too. A 2025 Hebrew University report identified THC inhibition of peripheral nociceptors via NaV1.7 and NaV1.8 nociceptive sodium channels. That is a serious finding because NaV1.7 and NaV1.8 are core pain targets, and the mechanism sits outside CB1/CB2. It also fits a larger translational push. In 2026, ScienceDaily highlighted research on “a cannabis compound that relieves pain without the high.” The exact compound and clinical prospects need careful scrutiny, but the direction is credible: analgesia can, at least in principle, be separated from central intoxication by targeting peripheral or non-CB1 pathways.

Affinity, efficacy, bias, and concentration windows

This broader target map only makes sense if the pharmacology terms are clear. Ki is a binding affinity constant: lower Ki usually means tighter binding in a competition assay. EC50 is the concentration producing 50 percent of a measured functional effect. They are not interchangeable. A ligand can bind tightly yet produce weak signaling, or bind modestly yet strongly shift function through amplification in a pathway.

An agonist activates a receptor. An antagonist blocks activation by another ligand. An inverse agonist pushes constitutively active receptors toward lower baseline signaling. THC at CB1 is usually described as a partial agonist: even when it occupies receptors, it does not produce the full effect of a high-efficacy agonist. That helps explain why different cannabinoids, and even different synthetic CB1 ligands, can have very different physiological ceilings.

Signaling bias means one ligand stabilizes receptor conformations that favor one pathway over another, such as G protein signaling over β-arrestin recruitment. This is now standard drug-development thinking, including in cannabinoid medicinal chemistry; the 2016 Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands” sits in that target-directed tradition. Desensitization means repeated or sustained activation can reduce responsiveness, a major issue for TRP channels and for CB1 itself. Finally, tissue-specific target engagement means the same compound can hit different targets in brain, gut, skin, immune cells, or peripheral nerves depending on concentration, route, metabolism, and local protein expression. That is why in vitro promiscuity does not automatically equal clinical relevance—but it is also why CB1/CB2-only explanations keep failing.

TRP channels: the heat, pain, and irritation sensors cannabinoids keep hitting

The usual shorthand says cannabinoids act through CB1 and CB2. That is too narrow to explain what many of these molecules actually do in tissue. Again and again, phytocannabinoids hit transient receptor potential channels, a superfamily of ion channels that sit in nociceptors, keratinocytes, airway nerves, immune cells, and other sensory interfaces where the body detects heat, cold, chemicals, stretch, injury, and inflammation.

This biology is not obscure. It was central enough to somatosensory science that the 2021 Nobel Prize in Physiology or Medicine went to David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch.” Julius’s work identifying capsaicin’s receptor, TRPV1, helped establish the modern view that pain signaling is not just a wire carrying damage information; it is chemically gated at the very first sensory ending. That matters for cannabinoids because several major plant cannabinoids interact with the same molecular hardware that responds to chili pepper, mustard oil, noxious heat, cooling agents, acidic conditions, and inflammatory lipids.

The result is a pharmacology that looks messy if you expect one receptor and one effect. It makes more sense if you think in terms of sensory gain control. Many cannabinoids are weak-to-moderate ligands at CB receptors and, at the same time, direct modulators of TRP channels. Some activate them. Some inhibit them. Some do both depending on concentration, species, splice variant, membrane environment, and whether the assay is measuring calcium influx, current, neuropeptide release, or behavior in an animal.

TRPV1, TRPA1, TRPV2, and TRPM8 in sensory biology

TRP channels are polymodal detectors. TRPV1 is the best known: activated by capsaicin, noxious heat, protons, and endogenous inflammatory mediators, it is heavily expressed in small-diameter sensory neurons that drive burning pain and neurogenic inflammation. Open the channel, and cations flow in, depolarizing the neuron and increasing intracellular calcium. TRPA1 often sits in overlapping nociceptor populations and is famous for detecting electrophilic irritants such as allyl isothiocyanate from mustard and wasabi, acrolein in smoke, and oxidant stress products generated during inflammation. It is relevant not only to pain but also to itch, cough, airway hyperreactivity, and migraine-like trigeminal signaling.

TRPV2 is less straightforward. It is a high-threshold thermo- and mechanosensitive channel in some systems, but it is also found in immune cells, glia, and proliferative tissues, which is why it keeps appearing in discussions of inflammation and, more speculatively, cancer biology. TRPM8, by contrast, is the canonical cool sensor activated by cold temperatures and compounds like menthol and icilin. Yet it also matters in pain states, where cold allodynia can become severe, and in some contexts TRPM8 activity can suppress pain through circuit-level counterstimulation. Same family, very different sensory roles.

That spread of functions explains why cannabinoid effects can look contradictory on the surface. Activating TRPV1 or TRPA1 can sting. Blocking TRPM8 can reduce cooling sensations but may also alter cold pain. Stimulating TRPV2 in one cell type can affect calcium signaling without producing any obvious sensory effect at all. There is no single “TRP effect” any more than there is a single “cannabinoid effect.”

CBD, CBG, CBC, and THC at TRP-family channels

Among phytocannabinoids, CBD has the strongest and most replicated TRP profile. In heterologous expression systems, CBD activates human TRPV1, TRPA1, and TRPV2 at micromolar concentrations and inhibits TRPM8. A widely cited study by De Petrocellis and colleagues in 2011, using calcium imaging in transfected HEK-293 cells, found that CBD behaved as an agonist at TRPV1, TRPV2, TRPA1, and TRPV4, while antagonizing TRPM8. The potency was not uniform: TRPA1 was especially sensitive, with low-micromolar activity, whereas other channels required somewhat higher concentrations. That pattern has held up well enough that TRP engagement is now part of any serious account of CBD pharmacology.

CBG and CBC fit the same general theme, though with their own fingerprints. CBG has repeatedly shown activity at TRPA1 and TRPV1, along with inhibition of TRPM8, making it pharmacologically interesting for inflammatory pain and visceral hypersensitivity models. CBC is less studied than CBD, but available in vitro work suggests it also activates TRPA1 and can engage TRPV1. These are not tiny curiosities found in one assay and never seen again. They recur across recombinant systems and primary sensory preparations, which is exactly why they keep resurfacing in mechanism papers on analgesia and inflammation.

THC is more complicated. It can activate TRPV2 and has been reported to interact with TRPA1 and TRPV1 under some conditions, but its pharmacology is dominated in many experiments by CB1-mediated effects, especially in the central nervous system. Even so, the idea that THC is only a CB1 drug is wrong. Recent work from Hebrew University, reported in 2025, argued that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 sodium channels, a separate non-CB mechanism that fits with the broader point here: cannabinoids often hit multiple pain-relevant targets at once. TRP channels are part of that wider non-CB map.

A caution is necessary. Much of this evidence comes from micromolar assays, and not every micromolar in a dish corresponds to an achievable free concentration at a human target site. Lipophilic cannabinoids partition into membranes, bind proteins, and generate metabolites; route of administration and tissue accumulation matter. The fact that CBD oral solution is FDA-approved for seizure disorders does not prove that TRPV1 or TRPA1 drive its clinical effects in epilepsy. It simply shows that CBD clearly does things in humans that cannot be captured by calling it a “non-intoxicating CB receptor compound.” The molecular story is larger than that label.

TRP activity is also assay-sensitive. A channel may look like it is being “activated” in a calcium assay because intracellular stores, membrane potential, or endogenous lipids are changing in parallel. Species differences can be real. So can state dependence. Inflamed tissue acidifies, oxidizes, and produces lipid mediators, all of which reshape TRP gating. A cannabinoid that barely moves a channel at baseline may have a much bigger effect in an injured nerve ending.

Desensitization, analgesia, and why activation can reduce pain

This is the piece that confuses non-specialists: if TRPV1 and TRPA1 are pain-producing channels, why would activating them ever reduce pain?

Because acute activation and sustained functional output are not the same thing.

TRPV1 is the classic example. Capsaicin initially burns, then desensitizes nociceptors and can produce analgesia after repeated or high-concentration exposure. Clinically, that principle is used in the 8 percent capsaicin patch for neuropathic pain. The mechanism includes calcium-dependent desensitization, depletion of neuropeptides such as substance P and CGRP, altered channel phosphorylation state, and in some cases reversible defunctionalization of the nerve terminal. A channel that fires hard at first can become less responsive afterward. The immediate signal is pro-nociceptive; the downstream state can be anti-nociceptive.

Cannabinoids appear to exploit the same logic. CBD activation of TRPV1 or TRPA1 can trigger calcium entry, followed by reduced channel responsiveness and dampened excitability in sensory neurons. That is one plausible route by which a compound can sting in a petri dish yet reduce hyperalgesia in an animal. The time axis matters. So does dose. Low concentrations may sensitize or weakly activate. Higher concentrations may drive desensitization or even broader membrane effects that suppress firing.

TRPA1 adds another layer because it is deeply tied to inflammatory irritants and oxidative stress. In airway and trigeminal systems, repeated or prolonged activation can alter neuropeptide release and reflex responsiveness. That makes it relevant to cough, migraine, and inflammatory flare states, not just to “pain” in the narrow sense. If a cannabinoid engages TRPA1 and then reduces subsequent responsiveness, the net effect may be less irritation signaling even though the first molecular event was channel opening.

TRPM8 shows the opposite type of cannabinoid pattern in many assays: cannabinoids such as CBD and CBG often inhibit it rather than activate it. That could matter in cold hypersensitivity, where excessive TRPM8 signaling contributes to painful cold allodynia. Here there is no paradox of activation leading to relief; the simpler hypothesis is direct suppression of a cold-sensing pathway. But even this should not be oversold. In some pain states TRPM8 activity can counteract heat pain or itch, so blocking it is not automatically beneficial.

The strongest position the evidence supports is this: TRP channels are not side notes in cannabinoid pharmacology. They are recurring, functionally relevant targets, especially for peripheral sensory effects involving heat, chemical irritation, inflammatory pain, itch, and airway reflexes. They do not explain everything. They are not always the dominant mechanism in vivo. Yet anyone trying to understand why CBD, CBG, CBC, or even THC can alter pain and inflammation without a neat correspondence to CB1 or CB2 needs TRPV1, TRPA1, TRPV2, and TRPM8 on the page early, not as an afterthought.

That matters for drug development too. Public-health agencies are already distinguishing familiar cannabinoids from chemically altered or enhanced intoxicants because target-level differences can change risk. The same principle applies in reverse for therapeutics: if analgesia can be separated from central intoxication, one route is to design compounds that bias action toward peripheral TRP channels and other non-CB targets rather than strong brain-penetrant CB1 agonism. The old receptor-reductionist story is too small for the data.

PPARs: cannabinoids as intracellular lipid signals, not just membrane receptor ligands

Peroxisome proliferator-activated receptors, usually shortened to PPARs, change the cannabinoid conversation because they sit in a different place and work on a different clock from CB1 and CB2. CB1 and CB2 are membrane G protein-coupled receptors built for fast signaling: seconds to minutes, ion channels, neurotransmitter release, kinase cascades. PPARs are nuclear receptors. They respond to lipophilic molecules, move transcriptional machinery, and reshape which genes a cell expresses over hours to days. That shift matters. It means some cannabinoid effects may look less like classic receptor agonism and more like lipid-regulated reprogramming of inflammatory tone, mitochondrial handling, fatty-acid oxidation, fibrotic signaling, and glial responses.

That is not a speculative stretch. Cannabinoids are highly lipophilic, accumulate in membranes, partition into intracellular compartments, and generate metabolites that can have different target profiles from the parent molecule. A drug class with those properties is almost designed to keep running into nuclear lipid sensors. PPARs are among the most plausible places where that happens.

What PPAR-alpha, PPAR-gamma, and PPAR-delta do

The three major PPAR isoforms overlap, but they are not interchangeable. PPAR-alpha is classically tied to fatty-acid catabolism. It is abundant in liver, heart, kidney, muscle, and other tissues that burn fat aggressively, and when activated it pushes transcriptional programs for beta-oxidation, ketogenesis, lipoprotein handling, and lower inflammatory signaling. Pharmacologists know it from fibrate drugs. In pain and inflammation research, PPAR-alpha also matters outside metabolism because it can suppress NF-kappaB-linked inflammatory gene expression and alter sensory signaling.

PPAR-gamma is the isoform that keeps appearing in cannabinoid papers, sometimes for good reasons and sometimes because it is the easiest story to tell. It is highly relevant to adipocyte differentiation and insulin sensitivity, but that shorthand undersells it. PPAR-gamma regulates macrophage polarization, cytokine production, oxidative stress responses, fibrotic remodeling, endothelial behavior, and glial activation in the central nervous system. That gives it obvious relevance to inflammatory bowel disease, neuroinflammation, diabetic complications, and tissue fibrosis. It is also a double-edged target: strong activation can improve insulin sensitivity yet bring edema, weight gain, and other liabilities familiar from thiazolidinedione drugs.

PPAR-delta, also called PPAR-beta/delta, gets less attention in public cannabinoid writing, but it should not. It is widely expressed and supports fatty-acid use, mitochondrial function, wound repair, keratinocyte biology, and some anti-inflammatory programs. Depending on context, it can either restrain or facilitate disease processes, which is one reason the literature around it is less tidy. If a cannabinoid or cannabinoid metabolite engages PPAR-delta, the biological readout may vary by tissue much more than a simple “agonist equals benefit” story suggests.

Mechanistically, all three isoforms work as ligand-activated transcription factors that heterodimerize with retinoid X receptor and bind peroxisome proliferator response elements in DNA. Once engaged, they do not just flip one switch. They alter transcriptional networks. Co-activators, co-repressors, chromatin state, cell type, inflammatory context, and ligand-specific receptor conformation all influence the outcome. Two compounds can both be called PPAR-gamma agonists and still drive meaningfully different biology.

That point is especially important for cannabinoids, which are often pharmacologically promiscuous molecules rather than clean, single-target tools.

CBD and related cannabinoids in metabolic and inflammatory signaling

CBD is the recurring example because its clinical profile is poorly explained by CB1 or CB2 alone. The FDA-approved oral solution for seizures in Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex shows that CBD is pharmacologically real in humans, but not that any one non-cannabinoid target explains its actions. PPAR-gamma is one of the most cited candidates because multiple cell and animal studies have linked CBD to anti-inflammatory and metabolic effects that are attenuated by PPAR-gamma antagonists or accompanied by PPAR-gamma-dependent transcriptional changes.

A widely cited paper by O’Sullivan and colleagues in 2009 reported that CBD caused vasorelaxation in human arteries and that part of the effect was sensitive to the PPAR-gamma antagonist GW9662, suggesting a PPAR-gamma-dependent component. In 2011, Esposito and coauthors showed in an Alzheimer-like cell model that CBD reduced beta-amyloid-induced neuroinflammation and that blockade of PPAR-gamma reduced this protective effect. In 2013, Hind and O’Sullivan reviewed evidence that cannabinoids can activate PPARs directly or indirectly, placing CBD, THC, ajulemic acid, anandamide-related lipids, and several synthetic cannabinoids in the frame.

The pattern is consistent enough to take seriously: CBD often lands in experimental systems where inflammatory genes fall, oxidative stress markers drop, and PPAR-gamma antagonism weakens the response. But taking it seriously is not the same as treating it as settled. Many of these studies use micromolar CBD concentrations. That matters because intracellular free concentrations in living human tissues are hard to infer from nominal bath concentrations in a dish. CBD also binds and perturbs membranes, affects calcium handling, interacts with TRP channels, influences adenosine signaling by inhibiting nucleoside transport, and can alter endocannabinoid tone. Any of those routes can feed into transcriptional changes that later look “PPAR-like.”

Related cannabinoids add to the case without cleaning it up. THC has been reported in some systems to activate PPAR-gamma, though usually weakly compared with dedicated ligands. Cannabidiolic acid and tetrahydrocannabinolic acid have shown PPAR activity in selected assays. Endocannabinoid-related lipids such as palmitoylethanolamide, oleoylethanolamide, and some oxidized derivatives have stronger and more established relationships with PPAR-alpha and PPAR-gamma than the better-known phytocannabinoids do. This is one reason the intracellular lipid-signaling frame is better than a narrow “plant cannabinoids bind PPARs” frame. The active species may be the parent cannabinoid, a metabolite, a co-administered lipid mediator, or a downstream shift in endogenous lipid pools.

Ajulemic acid is a useful case study. It is a synthetic analog related to THC but intentionally developed away from classic intoxication. Across preclinical work it has shown anti-inflammatory and antifibrotic actions with evidence implicating PPAR-gamma among other targets. That sort of medicinal chemistry mirrors a broader trend in the field. By 2016, an ACS Journal of Medicinal Chemistry paper titled “Library Docking for Cannabinoid-2 Receptor Ligands” already reflected structure-based target engineering rather than crude receptor labels, and newer cannabinoid programs increasingly aim to separate analgesia, anxiolysis, or immunomodulation from central CB1 activation. The same logic applies to PPAR-active scaffolds: if useful cannabinoid biology can be extracted through transcriptional and peripheral mechanisms, there is no reason drug development must stay trapped inside THC-like pharmacology.

CBD’s metabolic signaling data are more mixed than its anti-inflammatory data. Some preclinical studies suggest improved insulin sensitivity, reduced inflammatory adipokines, or better mitochondrial handling. Others do not show major benefit, and human evidence is thin. Public discussion often runs ahead of the data here. The fact that PPAR-gamma controls glucose and adipose biology does not mean CBD is a clinically meaningful metabolic modulator in humans at standard exposures.

Gene transcription, delayed effects, and evidence limits

PPAR biology forces a timing correction. If a cannabinoid effect appears within seconds or a few minutes, PPARs are unlikely to be the primary explanation. Nuclear receptor signaling generally requires ligand access to intracellular compartments, receptor engagement, altered co-regulator recruitment, transcriptional changes, and then protein-level consequences. That takes time. Hours are plausible. Days are common. When papers claim that a cannabinoid’s rapid effect is “via PPAR-gamma,” skepticism is appropriate unless the design clearly separates immediate non-genomic signaling from later transcription-dependent outcomes.

Assay design is the recurring problem. Reporter assays can show that a compound increases PPAR-dependent transcription, but reporter systems are artificial and can exaggerate weak activity. Antagonist studies are informative, yet drugs like GW9662 are not magic truth serum; off-target effects and partial blockade complicate interpretation. Binding assays help, but direct binding does not guarantee that tissue exposure reaches the needed concentration in vivo. Knockout models are stronger, though compensation by other pathways can blur results. The best evidence stacks methods: direct target engagement, receptor-selective pharmacology, genetic disruption, relevant tissue concentrations, and a time course consistent with transcriptional action. Much of the cannabinoid-PPAR literature does not reach that standard.

PPAR-gamma’s prominence in CBD research is therefore both justified and overstated. Justified, because the signal recurs across vascular, inflammatory, neurodegenerative, and fibrosis-related models. Overstated, because CBD is exactly the kind of lipophilic, many-target molecule for which intracellular concentration, active metabolites, and assay context can create seductive but incomplete mechanistic stories. A fall in TNF-alpha or IL-6 after CBD exposure is not a fingerprint. It is a clue.

Still, the broader point holds. Cannabinoids should not be treated only as ligands for membrane cannabinoid receptors. Some act, directly or indirectly, as intracellular lipid signals that can engage nuclear transcriptional machinery. That opens plausible routes to anti-inflammatory, antifibrotic, and neuroimmune effects that are slower, less tied to intoxication, and potentially more relevant to long-term disease modification than acute CB1 signaling. It also raises a regulatory lesson. As authorities have stressed in other contexts, including the 2025 HHS statement that enhanced 7-hydroxymitragynine products pose “an imminent hazard to public safety,” molecule-level differences matter. Small structural changes can redirect target engagement. For cannabinoids and cannabinoid-like products, that means the safety and efficacy story cannot be inferred from THC familiarity alone, and PPAR biology is one reason why.

GPR55, GPR18, GPR119 and the orphan-GPCR problem

An orphan GPCR is a G protein-coupled receptor whose endogenous ligand, physiological role, or both remain uncertain. A deorphanized receptor is one for which a convincing endogenous activator has been proposed and replicated well enough to support a working biology. That sounds tidy. In practice, it rarely is. Cannabinoid pharmacology keeps running into this mess because endocannabinoids and phytocannabinoids are lipophilic, membrane-active, and promiscuous: they can shift calcium flux, kinase activity, or transcription in ways that look receptor-mediated even when the direct target is unsettled. This is exactly how GPR55, GPR18, and GPR119 entered the conversation as “nonclassical cannabinoid receptors.”

The temptation to mint a new receptor label is strong. It makes headlines. It also outruns the evidence. GPR55 came closest to being branded “CB3,” but the field never achieved the coherence that supported CB1 and CB2. The same caution applies even more strongly to GPR18 and GPR119.

Why GPR55 was once called a possible cannabinoid receptor

GPR55 was cloned in 1999, and early expression surveys placed it in tissues relevant to cannabinoid biology: brain regions, dorsal root ganglia, spleen, gastrointestinal tract, vasculature, immune cells, and bone-related cells including osteoclasts and osteoblast-lineage populations. That distribution mattered. A receptor expressed in pain pathways, inflammatory tissues, and bone immediately invites comparison to CB1 and CB2, especially when cannabinoid ligands seem to move its readouts.

Its signaling profile also looked different enough to be interesting. Unlike CB1 and CB2, which mainly couple to Gi/o and tend to inhibit adenylyl cyclase, GPR55 most often signals through Gα12/13 and sometimes Gq-linked pathways, activating RhoA, phospholipase C, ERK, and intracellular calcium release. In cell assays, the signature readout is often a calcium transient. That made GPR55 easy to “see” in heterologous systems, but also easy to overcall, because calcium assays are sensitive to receptor density, cell background, ligand lipophilicity, and assay timing.

The specific reason GPR55 became a cannabinoid-receptor candidate was that several cannabinoids and cannabinoid-like ligands produced measurable effects at it. Ryberg and colleagues, writing in the British Journal of Pharmacology in 2007, reported that GPR55 could be activated by multiple cannabinoid ligands and proposed it as “a novel cannabinoid receptor.” That paper became the historical hinge. It did not settle the question; it created it.

Soon after, the cracks showed. Some groups found that lysophosphatidylinositol, especially 2-arachidonoyl LPI species, was a more convincing endogenous agonist than any classical cannabinoid. Oka and colleagues in 2007 and later follow-up work pushed that view strongly. Others observed that compounds often discussed in cannabinoid research behaved inconsistently at GPR55: cannabidiol (CBD) commonly looked like an antagonist or negative modulator in some assays, while Δ9-THC was weak, partial, or inactive depending on the system. Abnormal cannabidiol, O-1602, and certain synthetic cannabinoids sometimes showed clearer activity than THC itself. That is not what one expects from a clean third cannabinoid receptor.

Still, GPR55 biology is real, even if the label is unstable. In pain research, the receptor is expressed in sensory neurons and spinal circuits, and genetic or pharmacological interruption of GPR55 signaling has reduced mechanical hypersensitivity in some rodent models. Staton and colleagues in Pain (2008) linked GPR55 activation to inflammatory and neuropathic pain processing, with antagonism reducing hypersensitivity. Yet the effect is not universal across models or ligands. Some data suggest pronociceptive signaling through calcium mobilization and increased neuronal excitability; other datasets are weaker or model-limited. The safest reading is that GPR55 can contribute to pain signaling in some contexts, particularly inflammatory states, but it is not a master pain switch.

Bone biology offers a firmer signal. Why? Because GPR55 knockout phenotypes are harder to dismiss as assay artifacts. In 2009, Whyte and colleagues reported in PNAS that mice lacking GPR55 showed increased bone mass and impaired osteoclast function, arguing that GPR55 promotes osteoclast resorption. This made mechanistic sense with its calcium- and RhoA-linked signaling. Osteoclasts depend on cytoskeletal rearrangement and localized calcium handling; GPR55 fits that machinery better than CB1 does. If a cannabinoid or cannabinoid-like compound modulates GPR55 here, the physiological consequence could be substantial.

Inflammation is the third major theme. GPR55 is present in immune-related cells, and its activation has been linked to cytokine release, leukocyte behavior, and vascular inflammatory responses. But again, the direction is not perfectly uniform. In some preparations GPR55 activation looks pro-inflammatory, in others more regulatory, which likely reflects cell type, ligand bias, and receptor cross-talk rather than simple contradiction. A receptor that couples through multiple pathways and sits in different membrane environments will not produce one universal output.

That complexity explains the long-running agonist/antagonist fight in the cannabinoid literature. CBD is the clearest example. Across several studies, CBD has often behaved as a GPR55 antagonist or functional inhibitor, blunting LPI-driven calcium signaling. Lauckner et al. in 2008, in a widely cited PNAS paper, showed that GPR55 activation increased intracellular calcium and promoted neurotransmitter release, while CBD countered aspects of that signaling. This has fed a persistent hypothesis that some CBD effects, especially in seizure and inflammation models, may partly involve GPR55 blockade rather than CB1 or CB2 action. That idea is plausible. It is not proven as the dominant mechanism in humans.

THC is even messier. Some reports classify it as a low-potency GPR55 agonist; others find negligible efficacy; still others suggest behavior that depends on receptor reserve or pathway measured. A ligand can look like an agonist in a β-arrestin assay, neutral in binding, and antagonistic in a calcium assay if the system is overexpressed or biased. That is not a technical footnote. It is the story.

The mixed evidence for GPR18 and GPR119

GPR18 has often been discussed because it responds in some systems to N-arachidonoyl glycine, an endocannabinoid-related lipid, and because abnormal cannabidiol and related compounds have shown vascular or immune effects that some authors mapped onto GPR18. Expression has been reported in immune cells, microglia, spleen, and some peripheral tissues. That made it attractive as a candidate for inflammatory regulation, immune trafficking, and possibly pain.

But the pharmacology has been uneven from the start. Kohno and colleagues in 2006 supported GPR18 activation by N-arachidonoyl glycine. McHugh and colleagues later linked GPR18 to microglial migration and inflammatory signaling. Then replication problems arrived. Some laboratories could not reproduce ligand responses in transfected systems. Others found strong dependence on receptor tagging, cell line, or species ortholog. A receptor that “works” only in one assay architecture is not deorphanized in any stable sense. For cannabinoids specifically, the evidence is weaker than popular summaries imply. There may be real biology here, but the case for GPR18 as a bona fide cannabinoid receptor remains thin.

GPR119 is different. It is much less plausible as a cannabinoid receptor, despite occasional inclusion in broad “non-CB” receptor lists. GPR119 is primarily associated with lipid sensing in pancreatic β cells and enteroendocrine cells, coupling through Gs to raise cAMP and promote glucose-dependent insulin secretion and incretin release. Oleoylethanolamide is a better-established endogenous ligand candidate than any classical cannabinoid. Because some fatty acid ethanolamides are structurally adjacent to endocannabinoid chemistry, GPR119 can be dragged into cannabinoid discussions by association. That is mostly category confusion. The overlap is chemical neighborhood, not strong evidence that THC, CBD, or major phytocannabinoids act meaningfully through GPR119 at physiologic concentrations.

What orphan receptor pharmacology gets wrong in headlines

The standard media failure is simple: one positive signaling assay becomes “scientists discovered a new cannabinoid receptor.” That leap ignores at least four filters.

First, assay dependence. Calcium mobilization, β-arrestin recruitment, ERK phosphorylation, dynamic mass redistribution, and radioligand binding do not ask the same question. A lipophilic ligand can perturb membranes, alter receptor trafficking, or show pathway bias. If the receptor is overexpressed, weak compounds start looking strong.

Second, species differences. Human GPR55 is not mouse GPR55 in every pharmacological detail, and the same is true for GPR18. A ligand profile built in HEK293 cells with the human receptor may not predict a rat pain study.

Third, concentration. Many cannabinoid papers report micromolar activity in vitro. That can matter pharmacologically, but not automatically. Tissue levels after inhalation, oral dosing, first-pass metabolism, or local accumulation in fat and membranes vary enormously. In vitro binding is not clinical mechanism.

Fourth, context. A receptor in immune cells may mediate one effect; the same receptor in osteoclasts, another. Add cross-talk with TRP channels, PPARs, serotonin receptors, and even sodium channels, and the clean one-ligand/one-receptor story breaks down fast.

That is why “CB3” has never stuck. GPR55 has credible biology in calcium signaling, pain, bone remodeling, and inflammation. It also has contradictory cannabinoid pharmacology, heavy assay sensitivity, and a strong competing claim that LPI-family lipids are its primary physiological ligands. GPR18 is more uncertain still. GPR119 mostly does not belong in the same basket except as a reminder that lipid GPCRs are easy to over-associate with cannabinoids.

For cannabinoid science, the lesson is restraint. These receptors may matter a great deal. They just do not justify premature renaming.

Serotonin signaling: where cannabinoids intersect with 5-HT systems

Serotonin is where a lot of popular claims about CBD become both more plausible and more slippery. The plausible part is straightforward: across cell assays, rodent anxiety models, stress paradigms, and a small number of human experimental studies, 5-HT1A keeps showing up as a meaningful node in CBD’s behavioral effects. The slippery part is that “acts on serotonin” can mean several different things. It might mean direct agonism at the orthosteric site. It might mean positive allosteric modulation. It might mean facilitation of receptor signaling without high-affinity binding. Or it might mean that CBD changes network activity upstream or downstream of serotonergic neurons, producing a serotonin-dependent result without being a classic serotonin-receptor drug at all.

That distinction matters. A lot. If a compound calms behavior in a way blocked by a 5-HT1A antagonist such as WAY-100635, that does not by itself prove the compound is a 5-HT1A agonist. It proves dependence on 5-HT1A signaling in that model. Those are not the same claim, and cannabinoid coverage often blurs them.

5-HT1A and the anxiety question

The strongest serotonin link for cannabinoids, especially CBD, is 5-HT1A. This receptor is a Gi/o-coupled serotonin receptor expressed both as an autoreceptor on raphe serotonergic neurons and as a postsynaptic receptor in anxiety-relevant regions including the hippocampus, amygdala, and prefrontal cortex. Drugs that activate or recruit this system can reduce anxiety in some settings, but receptor location matters: turning down serotonergic firing through autoreceptors is not the same thing as shaping postsynaptic signaling in limbic circuits.

CBD entered this discussion through preclinical work in the 2000s and 2010s showing anxiolytic-like effects in tests such as the elevated plus maze, Vogel conflict test, and contextual fear paradigms, with partial blockade by WAY-100635. One widely cited paper is Campos and Guimarães, 2008, which found that intra-prelimbic CBD reduced restraint-stress-related cardiovascular responses and that 5-HT1A mechanisms contributed to the effect. Another important human study is Bergamaschi et al., 2011: in a simulated public speaking test, 600 mg oral CBD reduced anxiety in subjects with social anxiety disorder relative to placebo. That paper did not prove 5-HT1A mediation in humans, but it fit the preclinical pattern and helped make serotonin a serious candidate mechanism rather than a marketing phrase.

The receptor pharmacology, though, never resolved into a simple “CBD is a serotonin agonist” story. Early in vitro work suggested CBD could displace ligands at human 5-HT1A receptors and behave as an agonist in some signaling assays, but the affinities were modest and assay-dependent. Russo and colleagues in 2005 reported CBD as an agonist at cloned human 5-HT1A receptors in [35S]GTPγS binding assays. That finding was influential, but later work complicated it. Some groups saw weak direct activity. Others saw functional enhancement better explained by allosteric or membrane-level effects. The literature is consistent on one point only: 5-HT1A matters more for CBD’s anxiety-related pharmacology than CB1 or CB2 alone can explain.

This is why receptor reductionism fails. If CBD were simply a clean 5-HT1A agonist, its profile should resemble known serotonergic anxiolytics more neatly than it does. Instead, the behavioral signal is highly context-dependent, often showing inverted-U dose-response curves. In some rodent tests, moderate doses reduce anxiety-like behavior while lower or higher doses do less. That is a red flag against one-receptor storytelling. TRPV1 activation at higher concentrations is one proposed reason. So are effects on endocannabinoid tone, adenosine uptake, and intracellular calcium handling. A molecule can recruit 5-HT1A and still refuse to behave like a textbook 5-HT1A drug.

Direct binding versus indirect serotonergic effects

The best way to read the serotonin evidence is by tier. At the molecular level, there is support for direct interaction between CBD and 5-HT1A, but not the kind of clean, high-affinity, high-efficacy interaction that settles the question. Depending on the assay system, CBD has been described as a weak agonist, a partial agonist, or a positive allosteric modulator. The disagreement is not trivial semantics. Orthosteric agonists occupy the main serotonin-binding site. Positive allosteric modulators change receptor behavior from another site and may amplify endogenous serotonin responses without strongly activating the receptor on their own. Those mechanisms have different implications for dose, timing, side effects, and translation to humans.

Cell-signaling data often point to facilitation rather than brute-force activation. In some preparations CBD enhances 5-HT1A-mediated signaling cascades, including effects on ERK and other downstream pathways, more than would be predicted from its weak binding alone. There are several possible explanations. CBD is highly lipophilic and partitions into membranes, where it can alter receptor microenvironment and G-protein coupling. It can also raise anandamide signaling indirectly, and endocannabinoid-serotonin cross-talk in the dorsal raphe and forebrain is well documented. Then there is adenosine: CBD inhibits equilibrative nucleoside transporter activity in some systems, increasing extracellular adenosine and changing neuronal excitability in ways that can feed into serotonergic circuits. None of that makes 5-HT1A irrelevant. It makes it embedded.

Animal pharmacology gives stronger evidence for serotonin dependence than for direct agonism. Again and again, WAY-100635 attenuates CBD’s effects in anxiety, panic, nausea, and stress models. Resstel et al., 2009, for example, linked CBD’s attenuation of acute restraint stress responses to 5-HT1A mechanisms. Rock and Parker’s work on nausea and anticipatory nausea in rodents also implicated 5-HT1A in CBD’s antiemetic profile. These are useful results, but they should be read as pathway evidence. If blocking 5-HT1A removes the effect, the pathway is involved. It does not settle whether the receptor is being bound directly, modulated allosterically, or recruited through circuit-level changes.

Human evidence remains modest. The 2011 Bergamaschi study is often cited because it showed a measurable anxiolytic signal in social anxiety during public speaking. Smaller imaging studies have reported that CBD changes limbic and paralimbic activation during emotional processing tasks. Yet none of these studies identified 5-HT1A receptor occupancy in humans the way PET studies can for established serotonergic drugs. That absence is important. We are inferring mechanism from convergence, not measuring it directly at clinical doses.

Why CBD's calming profile resists simple receptor labels

CBD already has one FDA-approved use, and it is not anxiety. The 2024 FDA label for cannabidiol oral solution limits indication to seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients age 1 year and older. That fact is a useful check on overstatement. A compound can have credible anxiolytic signals without having anxiety efficacy settled at the regulatory level, and it can have serotonergic involvement without belonging neatly in the serotonin-drug box.

Part of the problem is scale. In vitro, cannabinoids are pharmacologically messy. In vivo, they are even messier because distribution, metabolism, tissue accumulation, and species differences change which targets matter. A receptor effect seen at 10 micromolar in transfected cells may be irrelevant after ordinary oral dosing, while a weaker-seeming effect in vitro may matter if the compound concentrates in lipid-rich brain tissue or if active metabolites contribute. This is one reason headlines about “the serotonin receptor CBD hits” tend to outrun the data.

Another reason is circuit biology. Anxiety is not generated by one receptor. It emerges from interactions among the amygdala, bed nucleus of the stria terminalis, medial prefrontal cortex, hippocampus, hypothalamus, and brainstem nuclei including the dorsal raphe. CBD appears to shift activity across this network. Some of that shift likely recruits 5-HT1A. Some may involve TRPV1, which can oppose anxiolysis at higher doses. Some may involve FAAH-related changes in anandamide tone, though human FAAH inhibition by CBD at therapeutic exposures is debated. Some may reflect anti-inflammatory or autonomic effects that feed back into perceived anxiety. Once that network view is adopted, the failure of a single-label explanation stops looking like a weakness and starts looking like a realistic account of the pharmacology.

This is also where drug development is heading. The medicinal-chemistry era is less interested in arguing whether a compound is “like THC” than in defining target combinations and separating desired effects from intoxication. That logic appears in work far outside serotonin, from CB2 structure-based screening in the 2016 Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands” to newer efforts to split analgesia from central impairment. It also appears in company-stage anxiolytic programs. In 2025, MIRA Pharmaceuticals said its candidate MIRA-55 showed a “differentiated mechanism of action” and “anxiolytic activity relative to THC” in preclinical data reported in a Nasdaq press release. The evidence tier needs to stay explicit here: preclinical, company-reported, not clinical proof. Still, the signal is meaningful as a market and research indicator. Firms are actively searching for cannabinoid-inspired agents that can calm without acting as THC does, and serotonin-facing mechanisms are part of that search.

The public-health context makes this more than an academic dispute. In 2025, HHS stated that 7-hydroxymitragynine “poses an imminent hazard to public safety” when backing scheduling action against dangerous enhanced 7-OH products. Different chemical modifications create different target profiles and different risks. The same lesson applies across the cannabinoid space. If a product is treated as interchangeable with familiar plant cannabinoids because it sounds adjacent to THC or CBD, pharmacology gets flattened and safety assessment suffers.

So where does the evidence land? 5-HT1A is the best-supported serotonergic mechanism for CBD’s calming effects, but the strongest claim the data currently support is not “CBD is a serotonin agonist.” It is narrower and more defensible: CBD often produces anxiolytic-like and stress-buffering effects that depend in part on 5-HT1A signaling, while the exact mode of engagement appears to vary by assay, dose, tissue, and circuit context. That may be less tidy than a one-receptor slogan. It is also much closer to the truth.

Beyond the requested list: sodium channels and other noncanonical targets already changing the pain conversation

For years, most public discussions of cannabinoid pain pharmacology have stayed trapped in a two-receptor story: CB1 explains the psychoactive effects, CB2 explains the immune effects, and everything else is treated as secondary. That framing is now too small. Even within the narrower pain field, cannabinoids do not just touch TRP channels, PPARs, orphan GPCRs, or serotonin-linked pathways. They also interact with voltage-gated sodium channels that sit at the core of nociceptor excitability. That matters because NaV1.7 and NaV1.8 are not peripheral side notes; they are among the most studied molecular gates for pain signaling in small-diameter sensory neurons.

The shift is more than academic. Drug developers have spent years trying to block pain transmission at the level of peripheral nerves without reproducing the sedation, intoxication, memory disruption, and abuse liability associated with strong central CB1 activation. If a cannabinoid, or a cannabinoid-derived scaffold, can dampen nociceptor firing by acting on NaV channels outside the brain, that opens a very different therapeutic logic. It moves the conversation away from “How strongly does it hit CB1?” and toward “Where does it act, at what concentration, and in which tissue?”

That broader target map also fits the larger regulatory moment. In 2025, the U.S. Department of Health and Human Services warned that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety,” a reminder that small chemical changes can produce very different pharmacology and safety profiles. Cannabinoid policy has often lagged behind this basic fact. Treating all intoxicant-adjacent compounds as if they differ only by source or THC-equivalent strength misses the point. Target-level pharmacology is what predicts effect, risk, and drug potential.

THC at NaV1.7 and NaV1.8 peripheral nociceptive channels

The most direct reason sodium channels now belong in any serious cannabinoid map is the 2025 report from the Hebrew University of Jerusalem group showing that THC inhibits peripheral nociceptors by targeting “NaV1.7 and NaV1.8 nociceptive sodium channels.” This is a meaningful expansion of the field’s vocabulary. NaV1.7 and NaV1.8 are heavily expressed in peripheral pain-sensing neurons, and their role in human pain biology is not speculative. NaV1.7 loss-of-function mutations can produce congenital insensitivity to pain; gain-of-function mutations can drive severe pain syndromes. NaV1.8 is similarly tied to inflammatory and neuropathic pain states because it supports repetitive firing in nociceptors, especially under depolarized conditions.

So when THC is shown to inhibit these channels, the finding does not belong in the “miscellaneous off-target effects” bucket. It points to a mechanism that could directly reduce the excitability of pain fibers before signals ever reach the spinal cord or brain.

That is a different mechanistic class from the better-known cannabinoid stories. TRPV1, recognized in the work that contributed to David Julius’s share of the 2021 Nobel Prize, can be activated or desensitized by several cannabinoids, including CBD and CBG, with effects that depend heavily on dose and timing. PPAR-gamma signaling has been invoked for anti-inflammatory and metabolic effects, often with the complication that intracellular accumulation and metabolites may matter as much as parent compounds. GPR55 remains debated enough that calling it “CB3” is still more slogan than settled science. Serotonin links, especially 5-HT1A, help explain parts of CBD’s anxiolytic profile, but the circuitry is context-dependent and often indirect. Sodium-channel inhibition is less glamorous. It is also, for pain, potentially more practical.

A key point here is pharmacological promiscuity. Cannabinoids are often “dirty” ligands in the technical sense: they engage multiple targets with different affinities and functional consequences. That is not a flaw in the science; it is the science. THC may still be best known for central CB1 agonism, but that does not cancel its ability to modulate peripheral ion channels under the right conditions. The real question is whether those conditions are reachable in vivo in ways that help patients more than they harm them. The Hebrew University finding says that this is at least plausible enough to deserve serious drug-development attention.

Peripheral analgesia without central intoxication

This is where the pain field gets interesting. A cannabinoid mechanism that reduces peripheral nociceptor firing could, at least in theory, separate analgesia from the cognitive impairment usually tied to brain CB1 activation. That distinction is the center of current translational work, not a side benefit.

The 2026 ScienceDaily report captured the idea in plain language: researchers identified “a cannabis compound that relieves pain without the high.” That phrasing should be read carefully. It is a research-stage signal, not established therapy, and popular summaries often compress mechanistic details. Still, the translational importance is obvious. If analgesic activity can be generated through peripheral restriction, limited brain penetration, selective non-CB1 target engagement, or some combination of the three, then the old tradeoff between pain relief and intoxication is not fixed by nature. It is a medicinal-chemistry problem.

That point also helps explain why the field has moved beyond crude receptor labels. The 2016 ACS Journal of Medicinal Chemistry paper, “Library Docking for Cannabinoid-2 Receptor Ligands,” reflects a broader shift toward structure-based design rather than treating cannabinoids as one pharmacological family with a single useful axis of variation. Chemists now ask how to tune scaffold shape, lipophilicity, receptor bias, tissue distribution, and metabolic fate. The goal is not just stronger activity. The goal is selective activity in the right place.

Peripheral analgesia is exactly the sort of endpoint where those distinctions matter. A compound that poorly crosses the blood-brain barrier, but meaningfully inhibits NaV1.7 or NaV1.8 in nociceptors, might ease inflammatory or neuropathic pain with far less intoxication than THC itself. That remains an ambition, not a clinical fact. Yet the Hebrew University work gives that ambition a molecular foothold.

It also sharpens how we think about cannabis products already in circulation. The legal definition of hemp in the 2018 Farm Bill hinges on delta-9 THC content “not more than 0.3 percent on a dry weight basis.” That number is regulatory, not pharmacological. It says nothing about sodium channels, TRP activation, 5-HT1A signaling, active metabolites, or tissue exposure. The same goes for newer enhanced or semi-synthetic intoxicants. Safety cannot be inferred from origin stories. It has to be inferred from targets, concentrations, and real pharmacokinetics.

Why these findings matter for future cannabinoid drugs

The strongest implication of the NaV1.7/NaV1.8 story is that future cannabinoid medicines may succeed precisely by being less “cannabinoid-like” in the popular sense. That is, the useful descendants of cannabis chemistry may not be drugs that broadly mimic smoked THC. They may be compounds that borrow part of the scaffold, avoid central CB1 signaling, and act instead on peripheral ion channels or mixed noncanonical target sets.

That possibility already fits the wider evidence base. CBD’s approved use is for seizure disorders, not routine analgesia, and even there its pharmacology is not well explained by CB1 or CB2 alone. The FDA label for cannabidiol oral solution states that it is indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year and older. In other words, the only major FDA-approved cannabinoid medicine in broad current use already resists the simplistic receptor narrative. The pain field is catching up to the same lesson.

Early company programs point the same way, though they require caution. In 2025, MIRA Pharmaceuticals reported preclinical data claiming that MIRA-55 showed a “differentiated mechanism of action” and “anxiolytic activity relative to THC.” Company press releases are not neutral evidence, and preclinical signals often fail. Even so, they show where medicinal chemistry is heading: away from undirected THC mimicry and toward mechanism-shaped design.

For pain, sodium channels may become one of the most consequential branches of that design strategy. Not the only branch. TRPV1, TRPA1, PPAR-gamma, GPR55, adenosine-linked pathways, and serotonergic modulation will stay in the picture. But NaV1.7 and NaV1.8 bring something especially attractive: a direct connection to the electrical behavior of peripheral pain fibers. That makes them unusually concrete targets in a field crowded with indirect explanations.

The result is a cleaner way to think about cannabinoids and pain. Not CB1 versus CB2. Not plant versus synthetic. And not “high” versus “medical” as if those are molecular categories. The better distinction is central intoxication mechanisms versus peripherally useful mechanisms. The Hebrew University finding places THC itself on both sides of that line. That is exactly why it matters.

How specific cannabinoids differ when you stop asking only about CB1 and CB2

Once you stop treating CB1 and CB2 as the whole story, the familiar cannabinoid roster looks much less tidy. These molecules are not clean keys for two locks. They are lipophilic, concentration-sensitive compounds that can hit ion channels, nuclear receptors, transport processes, orphan GPCRs, and in some cases voltage-gated sodium channels. That matters because pain, inflammation, seizure control, anxiety, and adverse effects often map poorly onto simple “CB1 agonist” or “CB2 agonist” labels.

CBD forced this shift more than any other cannabinoid. Its weak classic cannabinoid receptor efficacy made the old framework hard to defend, especially once an FDA-approved cannabidiol oral solution gained indications for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year of age and older. A clinically useful cannabinoid with limited CB1-like intoxication was a problem for receptor reductionism. Researchers had to look elsewhere.

The wider field followed. Work on TRP channels drew on sensory biology that was recognized at the highest level when the 2021 Nobel Prize in Physiology or Medicine went to David Julius and Ardem Patapoutian for discoveries of receptors for temperature and touch. Cannabinoid pharmacology intersects directly with that biology: TRPV1, TRPA1, and TRPM8 keep recurring because many phytocannabinoids can activate, inhibit, or desensitize them at experimentally relevant concentrations. That does not mean every assay result predicts a human effect. It does mean the old idea that “real” cannabinoid action begins and ends at CB1/CB2 is wrong.

CBD: the prototype of non-CB1/CB2 complexity

CBD is the best example of why target promiscuity matters. It has low affinity and limited efficacy at CB1 and CB2 compared with THC, yet it clearly does something biologically important. The gap between those two facts produced a series of working hypotheses, some stronger than others.

TRP channels were among the first serious alternatives. CBD activates TRPV1 in heterologous systems, and TRPV1 is not an obscure side path; it is a core nociception and inflammatory pain channel. Activation can sound counterintuitive if the therapeutic goal is analgesia, but repeated or sustained TRPV1 activation often produces desensitization, reducing subsequent excitability. That is one reason TRP pharmacology can look contradictory on paper. A compound may activate first and quiet the system later. CBD also shows actions at TRPA1 and can inhibit TRPM8 in some models, making it pharmacologically broader than the usual public summary of “non-intoxicating cannabinoid.”

The serotonin story is more contested but still important. A large preclinical literature links CBD to 5-HT1A-related effects, especially in anxiety, stress, and nausea models. The cleanest claim is not that CBD is a simple high-affinity 5-HT1A agonist in the way buspirone-related pharmacology is discussed, but that 5-HT1A signaling often contributes to CBD’s effects in vivo, sometimes through partial agonism, sometimes through allosteric or circuit-level mechanisms that remain unsettled. That distinction matters. Too many summaries flatten “involves 5-HT1A” into “works by serotonin.” The data do not support that simplification.

PPAR-gamma is another recurring candidate, and here intracellular chemistry matters. PPARs are nuclear receptors, so a lipophilic molecule that partitions into membranes and cells may affect them in ways a surface-receptor model misses. CBD has been reported to activate PPAR-gamma in cell systems, and PPAR-gamma signaling has plausible links to inflammation, lipid metabolism, fibrosis, and neuroinflammation. But there is a catch: some PPAR-related effects may reflect metabolites, longer exposure, or indirect changes in endogenous lipid mediators rather than one-step receptor occupation. The pharmacology is real enough to study seriously, but weaker as a slogan than as a mechanism.

Adenosine signaling entered the picture because CBD appears to inhibit equilibrative nucleoside transport in some systems, potentially raising extracellular adenosine tone and indirectly affecting A2A-linked anti-inflammatory pathways. Again, this is not tidy receptor binding pharmacology. It is transport pharmacology and tissue context. If that sounds messier than “CBD hits CB2,” it is. It is also more plausible.

Then there is GPR55, often floated as a putative “CB3.” That label is still too confident. CBD can antagonize or otherwise modulate GPR55-linked signaling in several experimental systems, and GPR55 has been implicated in excitability, bone biology, inflammation, and cancer-related pathways. But the receptor’s endogenous ligands, pathway coupling, and translational relevance remain debated. GPR55 is a useful hypothesis generator, not a settled replacement for CB1/CB2.

The upshot is simple: CBD became the prototype of non-CB1/CB2 cannabinoid pharmacology because its clinically relevant effects could not be explained otherwise. That is still true.

CBG, CBC, THCV, acidic cannabinoids, and minor-cannabinoid pharmacology

Minor cannabinoids are often sold to the public as if each has a single personality trait. Pharmacology does not cooperate.

CBG is usually described as mildly active at CB1 and CB2, but the more interesting signals sit outside those receptors. It interacts with alpha-2 adrenergic and 5-HT1A systems in some assays, shows activity at TRP channels, and has been studied for anti-inflammatory and analgesic effects that do not reduce neatly to classic cannabinoid receptor activation. It also illustrates a recurring problem: micromolar in vitro activity is easy to publish and hard to translate. A receptor hit at 10 micromolar may matter in a dish and not in human plasma, or it may matter only in tissues where the compound concentrates.

CBC has long been under-characterized relative to the hype around it. It appears to engage TRPA1 and TRPV family channels more convincingly than CB1, and some studies suggest anti-inflammatory or analgesic-like effects in animals. There is also interest in CBC’s interaction with endocannabinoid tone, including effects that could alter anandamide signaling indirectly. But “CBC works through TRP channels” is still a starting point, not a finished answer. Human evidence is very thin.

THCV is a more complicated case because it can behave differently by dose and context even at CB1, often described as a neutral antagonist or low-efficacy ligand at some concentrations and a more agonist-like compound in others. Outside CB1/CB2, THCV has been linked to TRP actions and metabolic effects, with repeated interest in appetite, glycemic control, and energy balance. Some of that enthusiasm outran the evidence years ago. The better interpretation is that THCV is pharmacologically interesting precisely because it does not fit the THC template, not because any one secondary target has fully explained its profile.

Acidic cannabinoids deserve more attention than they get. THCA and CBDA are often treated as simply “raw” precursors, but their pharmacology is not just inactive waiting to be decarboxylated. CBDA has some of the more intriguing evidence for 5-HT1A-related anti-nausea effects in preclinical work, and both acidic cannabinoids have shown TRP and enzyme-related actions in vitro. Their lower brain penetration relative to neutral cannabinoids may actually be an advantage for some peripheral or gastrointestinal targets. The problem is data quality and dose realism. Many claims rest on sparse animal studies or cell assays with uncertain human relevance.

This is where current policy and product chemistry collide with pharmacology. The 2018 Farm Bill defined hemp using a delta-9 THC threshold of not more than 0.3 percent on a dry weight basis. That legal boundary says nothing about GPR55, TRPV1, NaV1.7, metabolites, or semi-synthetic analogs. Regulators have started reacting to this mismatch in adjacent areas. In 2025, HHS said that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” when backing DEA action on enhanced 7-OH products. Different drug class, same lesson: modified or enriched products can have safety profiles that diverge sharply from the source material. Cannabinoids are not exempt from that logic.

Metabolites, entourage claims, and the chemistry problem

One reason cannabinoid pharmacology becomes slippery is that the parent compound is not always the whole exposure. Metabolites can matter, sometimes a lot. The public learned this mainly through intoxicating THC metabolites, but the broader principle applies across cannabinoid science. Route of administration, first-pass metabolism, tissue partitioning, and species differences can all change which targets are actually engaged.

Even THC, the compound most tightly associated with CB1, is not restricted to CB1 biology. In 2025, researchers from Hebrew University reported that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 nociceptive sodium channels. That is a major reminder that analgesia can involve direct effects on excitability machinery, not only GPCR signaling. A 2026 research report highlighted by ScienceDaily pushed the same translational idea further, describing a cannabis-derived compound that relieved pain without the high. That remains research-stage evidence, not settled medicine, but it points toward a serious drug-development strategy: separate analgesia from central intoxication by exploiting non-CB1 targets, peripheral restriction, or both.

Medicinal chemistry is moving in that direction. Structure-based screening around cannabinoid receptors was already well established by the 2016 Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands,” and newer efforts increasingly aim for differentiated mechanisms rather than generic “THC-like but weaker” compounds. A 2025 MIRA Pharmaceuticals release, which should be treated as company-reported preclinical data rather than independent confirmation, described MIRA-55 as having a differentiated mechanism and anxiolytic activity relative to THC. The important point is not that the claim is proven. It is that drug developers now assume target separation matters.

That brings us to the entourage effect. As a narrow scientific idea, it is plausible that combinations of cannabinoids, terpenes, and metabolites can shift pharmacokinetics or produce additive, opposing, or occasionally supra-additive effects across multiple targets. As a blanket explanation for why any mixed cannabis product supposedly works better, it is usually too vague to test and too elastic to falsify.

The chemistry problem is basic. A mixture containing THC, CBD, CBG, acidic cannabinoids, oxidized products, residual terpenes, and variable metabolites is not one intervention. It is many moving parts whose effects depend on concentration ratios and timing. Plausible multi-target pharmacology exists. Unsupported simplification exists too. Those are not the same thing.

The better standard is target-specific evidence tied to exposure. Which compound, at what concentration, in what tissue, producing what measurable effect? Once you ask those questions, the mythology fades and the real cannabinoid story comes into focus: not two receptors, but a crowded pharmacological map.

Methods matter: why assay design shapes what we think cannabinoids do

Claims about cannabinoid targets often sound cleaner than the data behind them. A paper says CBD “activates TRPV1,” another says it is a “5-HT1A agonist,” a third calls GPR55 a cannabinoid receptor candidate, and a docking study proposes a neat pose in CB2 or some orphan GPCR pocket. Those statements may all be directionally useful. They are not all the same kind of evidence.

That distinction matters because cannabinoids are greasy, membrane-loving molecules with a bad habit of looking active in more places than they truly matter in vivo. The field has learned this the hard way. If a compound partitions into membranes, changes bilayer properties, accumulates inside cells, forms active metabolites, or only shows an effect at 10 to 50 micromolar, it can generate target stories that collapse when tested under stricter conditions. For cannabis pharmacology, methods are not a technical side issue. They decide which mechanisms survive.

Binding assays, functional assays, and docking studies

Start with the oldest and cleanest question: does the compound bind? In a radioligand binding assay, membranes or intact cells expressing a receptor are incubated with a known radioactive ligand plus increasing concentrations of the test compound. If the test molecule displaces the radioligand, investigators estimate affinity, often reported as Ki. This is useful. It is also limited. Binding says a molecule can occupy a site under assay conditions; it does not say what happens next.

That is why functional assays matter more than binding when people make claims about signaling. For TRP channels such as TRPV1, TRPA1, or TRPM8, researchers often use calcium-flux assays with fluorescent dyes. If channel opening lets calcium into the cell, fluorescence rises. The appeal is obvious: these assays scale well and can compare many compounds quickly. The problem is just as obvious if you know cannabinoids. Some cannabinoids are fluorescent, some perturb membranes, some release calcium indirectly from intracellular stores, and some trigger channel desensitization after initial activation. A single peak in a calcium trace can hide several mechanisms.

Patch clamp is slower but far more informative. It records ionic current directly. For ion channels, especially sodium channels such as NaV1.7 and NaV1.8, patch clamp can show whether the drug changes activation, inactivation, open probability, or current density. That is why the 2025 Hebrew University report on THC acting at peripheral nociceptors through NaV1.7 and NaV1.8 is methodologically important: direct electrophysiology can separate a real channel effect from a vague cell-based signal. If a cannabinoid reduces sodium current in nociceptors at concentrations achieved in peripheral tissue, that has more mechanistic weight for analgesia than another loose “receptor interaction” label.

GPCRs and nuclear receptors require different readouts. For GPCRs, investigators may measure cAMP, beta-arrestin recruitment, GTPγS binding, ERK phosphorylation, or calcium signals in engineered cell lines. These are not interchangeable. A cannabinoid can look like an agonist in one pathway, a partial agonist in another, and an antagonist in a third. That is not sloppiness; it is signaling bias. For PPAR-gamma, the common approach is a reporter assay in which a PPAR-responsive promoter drives luciferase. Light goes up, and the compound is called a PPAR activator. But reporter assays are several steps removed from direct target engagement. A lipophilic cannabinoid can alter transcription indirectly through cell stress, metabolism, or changes in endogenous lipid mediators.

Gene-expression readouts are even further downstream. If a paper shows that CBD changes inflammatory transcripts and the effect is reduced by a PPAR antagonist, that is suggestive, not definitive. The antagonist may be imperfect. The cells may make metabolites. The cannabinoid may be shifting adenosine tone, calcium handling, redox state, or membrane order. Mechanism by subtraction is fragile.

Then there is docking. Docking asks whether a small molecule can fit into a modeled or experimentally determined binding pocket and score favorably. Used well, it is medicinal chemistry triage. Used badly, it becomes decorative certainty. The 2016 ACS Journal of Medicinal Chemistry paper, “Library Docking for Cannabinoid-2 Receptor Ligands,” is a good entry point because it shows the logic at its best: structure-based screening can help prioritize scaffolds, identify plausible receptor-ligand contacts, and guide synthesis around CB2 selectivity. That is what docking is for. It generates hypotheses. It does not prove that a phytocannabinoid engages a target in living tissue, much less that the interaction explains analgesia, anxiety, or inflammation.

Species differences, metabolites, and membrane effects

Even strong in vitro signals can fail outside the assay dish because cannabinoid pharmacology is highly context dependent. Human and rodent receptors are not always functionally identical. A compound active at mouse TRPA1 or rat 5-HT1A-linked readouts may shift potency or efficacy in the human ortholog. The same warning applies to splice variants, receptor reserve, and cell background. A heavily overexpressed receptor line can make a weak ligand look important.

Metabolism adds another layer. Many cannabinoids do not stay in their parent form for long. THC becomes 11-hydroxy-THC; other structures form oxidized or conjugated metabolites that may differ sharply in target profile. Regulators are paying closer attention to this problem in adjacent drug-policy debates. In 2025, HHS stated that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety,” highlighting a broader lesson: enhanced or metabolically advantaged intoxicants can behave very differently from the parent compound. The cannabis field has parallel issues with semi-synthetic cannabinoids, novel isomers, and formulations designed to shift exposure. If you assay only the parent molecule, you may miss the species actually driving effects in vivo.

Membranes are the biggest quiet confounder. Cannabinoids are lipophilic enough to accumulate in bilayers and intracellular compartments. That means nominal bath concentration is often a poor proxy for concentration at the target. A 10 micromolar application in a cell assay may create a very high local membrane burden, which can alter channel gating or receptor behavior nonspecifically. It can also produce false negatives if the free aqueous concentration is much lower than expected because the compound sticks to plastic, serum proteins, or the membrane itself.

This is one reason high-concentration claims deserve skepticism. If a cannabinoid only affects a target above 20 or 30 micromolar, the first question should be whether that reflects a physiologically meaningful interaction or a membrane-driven artifact. TRP channels are especially vulnerable to overstatement here. They are genuine cannabinoid-responsive targets in some cases, but the effects can be biphasic, rapidly desensitizing, and highly concentration sensitive. A short calcium burst at high micromolar concentrations does not automatically mean a therapeutically relevant mechanism.

From ACS docking papers to real pharmacology

Medicinal chemistry thrives on simplification, but biology punishes oversimplification. The ACS CB2 docking paper illustrates the useful version of simplification: start with a receptor structure, screen libraries, prioritize candidates, synthesize analogs, test them in binding and functional assays, then learn from structure-activity relationships. That sequence can build real drugs. It can also reveal that the most attractive in silico pose belongs to a compound with poor permeability, unstable metabolism, biased signaling, or no meaningful activity in native cells.

The distance from docked pose to pharmacology is exactly where many cannabinoid claims fail. A docking image of CBD or CBG in TRPV1, 5-HT1A, GPR55, or PPAR-gamma is not evidence that the compound drives the relevant physiology in animals or humans. Real pharmacology needs convergence. Ideally that means direct target engagement at plausible concentrations, functional effects in native systems, loss-of-function evidence using antagonists or knockouts, pharmacokinetic support, and some link to behavior or clinical outcome.

When those layers line up, the story gets stronger fast. The current research push to separate analgesia from intoxication depends on that logic. The 2026 ScienceDaily report describing “a cannabis compound that relieves pain without the high” is interesting precisely because it points past crude THC equivalence and toward target-selective or peripherally restricted mechanisms. The same goes for preclinical programs such as MIRA-55, which a 2025 company release described as having a “differentiated mechanism of action” with anxiolytic activity relative to THC. Company statements are low on the evidence ladder. Still, they reflect where the field is heading: away from simple CB1/CB2 labels and toward engineered polypharmacology that can be measured, not assumed.

Readers should demand that same discipline from academic cannabinoid papers. Ask what assay was used. Ask whether the active concentration is realistic. Ask whether the effect survives electrophysiology, antagonists, knockouts, metabolism studies, and species translation. Most of all, ask whether the target claim explains the organism, not just the plate. That is how non-CB1/CB2 cannabinoid pharmacology stops being a collection of interesting hints and becomes real mechanism.

Evidence tiers: from cell dish to clinic

The literature on non-CB1/CB2 targets is rich because cannabinoids are chemically promiscuous. A single molecule can touch TRPV1, 5-HT1A-linked signaling, PPAR-gamma, GPR55, adenosine tone, and voltage-gated sodium channels depending on concentration, tissue, and metabolite profile. That makes for interesting mechanism papers. It does not automatically make for proven medicine. If there is one rule that keeps this field honest, it is simple: every step up the evidence ladder discards a large share of claims that looked convincing below it.

What preclinical evidence can and cannot prove

At the bottom of the ladder are binding assays, channel recordings, reporter systems, and cell cultures. These methods are indispensable. They are how researchers learned that cannabinoid pharmacology extends well beyond the classic receptors, and they are why receptor-reductionist cannabis explainers now look dated. The 2021 Nobel Prize recognized David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch,” a reminder that TRP biology is not peripheral trivia; it sits near the center of modern pain science. When cannabinoids activate or desensitize TRPV1, TRPA1, or related channels in a dish, that finding matters.

But a dish cannot tell you whether the same target engagement occurs at tolerated human doses. Many in vitro cannabinoid effects appear only at micromolar concentrations. Plasma levels after real-world dosing may be lower, more transient, or shifted into metabolites with different pharmacology. CBD is the classic example. It repeatedly shows actions that are hard to explain through CB1 or CB2 alone, which is why TRPV1, 5-HT1A, PPAR-gamma, GPR55, and adenosine pathways keep appearing in the literature. Yet the fact that CBD can modulate a target in cultured cells does not prove that this mechanism drives a clinical outcome in epilepsy, anxiety, pain, or inflammation.

Animal models are one step closer to medicine and still far from it. Rodent studies can show that a cannabinoid reduces allodynia, suppresses inflammatory markers, or changes anxiety-like behavior. They can even support target-specific stories with antagonists, knockouts, or peripheral restriction. The recent Hebrew University report is a good example of why this work is exciting: researchers reported that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 nociceptive sodium channels. That finding cuts against the lazy assumption that THC-related analgesia must be a CB1 story plus intoxication. If the effect holds up, it suggests pain-relevant action at the level of peripheral excitability itself.

Still, even strong animal work cannot prove that blocking NaV1.7/NaV1.8 with a cannabinoid will become a safe, effective human analgesic. Species differences matter. Dosing matters. Route matters. Behavioral readouts in mice can mislead. A pain signal dampened in a nerve prep or a formalin assay may not translate into relief for neuropathy, osteoarthritis, or post-surgical pain in people. The same caution applies to company announcements. In 2025, MIRA Pharmaceuticals said its candidate MIRA-55 showed a “differentiated mechanism of action” and “anxiolytic activity relative to THC” in preclinical data. That is legitimate as research-stage evidence. It is not a treatment claim, and it should not be treated like one.

The same translational caution applies to attractive headlines. ScienceDaily in 2026 highlighted work on “a cannabis compound that relieves pain without the high.” Maybe. That is a useful direction for drug design, especially if peripheral targets or non-CB1 mechanisms can separate analgesia from central intoxication. But “without the high” in a preclinical report is a hypothesis under test, not a settled fact about human therapy.

Approved cannabinoid medicine and the narrowness of current indications

Now move to the top of the ladder: approved-drug evidence. Here the field gets much narrower. The clearest U.S. example is cannabidiol oral solution. The FDA-approved label states that it is indicated “for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older.” That sentence is more informative than dozens of vague wellness claims because it names the drug form, the outcome, the diseases, and the age range.

Notice what the label does not say. It does not say CBD is approved for pain, generalized anxiety, insomnia, inflammatory bowel disease, neuroprotection, or broad “endocannabinoid balance.” It does not validate every proposed mechanism in the preclinical literature. Approval tells us that a specific cannabidiol product demonstrated efficacy and acceptable safety for specific seizure disorders in controlled studies. It does not settle whether TRPV1, GPR55, 5-HT1A, PPAR-gamma, intracellular calcium effects, or metabolite actions are the dominant clinical mechanism. Mechanism can remain partly unresolved even when efficacy is real.

This gap between approved indication and mechanism folklore is common in pharmacology. Plenty of drugs worked in patients before their full target map was understood. Cannabinoids are not unusual on that point. What is unusual is how often broad claims are reverse-engineered from scattered receptor findings and then spoken of as if they had already passed clinical testing.

The narrowness of current indications also matters for public-health discussions. Regulators are increasingly distinguishing familiar plant cannabinoids from altered, enhanced, or semi-synthetic intoxicants with different risk profiles. In 2025, HHS stated that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” when backing scheduling action on enhanced 7-OH products. That statement concerned kratom-related products, not cannabis, but the policy lesson carries over neatly: once manufacturers begin enriching, modifying, or synthesizing potent psychoactive molecules, shorthand based on plant origin becomes unreliable. Target-level pharmacology starts to matter a lot.

Why mechanism stories often outrun clinical data

They outrun it because mechanism stories are fast, vivid, and publishable. Clinical proof is slow and expensive. A cell paper can show that a cannabinoid activates TRPA1, antagonizes GPR55, or changes 5-HT1A signaling in a monthslong project. A convincing randomized trial for chronic pain may take years and still fail because the effect size is small, adverse effects limit dosing, or the preclinical target was never meaningfully engaged in patients.

Cannabinoid chemistry also invites overinterpretation. Structurally related compounds can have very different target profiles, and metabolism can remake the picture after administration. Route changes the story again. Oral dosing produces first-pass metabolites; inhalation changes kinetics; topical or peripheral formulations may favor local targets over central ones. Even the legal category “hemp” says little pharmacologically. The 2018 Farm Bill drew the line at delta-9 THC “not more than 0.3 percent on a dry weight basis,” a statutory threshold, not a biological one.

So the right reading of non-CB1/CB2 evidence is neither dismissal nor hype. The preclinical literature genuinely shows that cannabinoids are acting at more than CB1 and CB2. For pain especially, TRP channels and sodium channels deserve serious attention. For CBD, nonclassical targets are not optional side notes; they are probably central to explaining its profile. But plausibility is not efficacy, target engagement is not patient benefit, and approval of one cannabinoid medicine for a small set of seizure disorders does not ratify the much larger cloud of claims built from receptor diagrams, mouse behavior, and cell-dish results.

Safety, regulation, and why off-target pharmacology matters in public health

Public health problems do not line up neatly with receptor diagrams. A cannabinoid can be plant-derived, hemp-derived, semi-synthetic, or fully synthetic and still end up producing risks that are poorly predicted by its label, its source, or its legal category. That is the practical meaning of off-target pharmacology. Once a molecule touches TRP channels, serotonin receptors, PPARs, GPR55-like signaling systems, sodium channels, and other non-CB1/CB2 targets, the safety profile can shift in ways that matter for poisoning surveillance, product standards, impaired-driving policy, and dependence risk.

The mistake is not just scientific. It is regulatory. Cannabis policy has often treated “cannabinoid” as if it were already an explanation.

Enhanced intoxicants and the policy lesson from 7-OH

The clearest current warning does not even come from a classic cannabis constituent. In 2025, the U.S. Department of Health and Human Services stated that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” when supporting DEA action on enhanced 7-OH products. That sentence matters because it shows federal health authorities drawing a line between familiar botanical exposure and concentrated or chemically manipulated intoxicants that can behave very differently in real populations.

The policy lesson transfers directly to cannabinoids. A broad category term such as “hemp-derived,” “plant-based,” or even “cannabinoid-like” tells regulators almost nothing about what targets a compound engages at use-relevant concentrations. It also tells consumers almost nothing about potency, onset, duration, interaction risk, or abuse liability.

Enhanced 7-OH products became a public-health issue because chemistry changed exposure. When a market moves from trace natural occurrence to concentrated active ingredient, pharmacology stops being a trivia question and becomes the central safety issue. The same pattern has already appeared around semi-synthetic and structurally altered cannabinoids sold under the umbrella of hemp legality after the 2018 Farm Bill defined hemp by delta-9 THC concentration of “not more than 0.3 percent on a dry weight basis.” That dry-weight threshold is a crop definition, not a pharmacology standard. It does not screen for TRP activity, sodium-channel blockade, 5-HT1A signaling, GPR55 effects, or metabolites with longer persistence and different central nervous system penetration.

This is why off-target effects are not some obscure footnote. They are one route by which products marketed as adjacent to cannabis can generate unexpected harms. A compound framed publicly as “THC-like but legal” may differ in intrinsic efficacy at CB1, but it may also differ in far less visible ways: stronger cardiovascular stimulation, greater pro-convulsant or anxiogenic potential, more severe dysphoria, unusual sedation, or a toxicity profile shaped by metabolism rather than parent drug alone. Those possibilities are not hypothetical in the abstract; they are exactly why health agencies react differently to enhanced intoxicants than to broad plant categories.

A sound policy response starts from target-level questions. What receptors and channels are engaged? At what concentrations? In which tissues? What are the major metabolites? Is there evidence of sodium-channel inhibition that might alter nociception or cardiac conduction? Is TRPV1 activation likely to desensitize pain signaling, or to irritate and worsen symptoms at lower or transient exposures? Those are harder questions than “is it a cannabinoid,” but they are the right ones.

The limits of THC-equivalence thinking

THC-equivalence is attractive because it simplifies law, taxation, labeling, and impairment discussions. It is also often wrong. Two compounds can produce some degree of intoxication and still differ sharply in anxiety liability, psychotomimetic potential, analgesic effect, heart-rate response, emesis control, tolerance development, and withdrawal burden because they do not share the same wider target map.

Even THC itself is not pharmacologically exhausted by CB1 and CB2. In 2025, researchers at Hebrew University reported that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 nociceptive sodium channels. That finding cuts against crude “THC acts here, CBD acts there” storytelling. If a canonical psychoactive cannabinoid can directly affect pain-relevant voltage-gated sodium channels, then safety and efficacy cannot be inferred from cannabinoid branding alone. Dose, route, distribution, and tissue exposure become decisive.

The same point appears from the opposite direction with CBD. Its approved oral solution is indicated by the FDA for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year and older, a clinical fact that was never well explained by CB1 agonism because CBD is not a straightforward CB1 intoxicant. Its profile has long pushed researchers toward other mechanisms, including TRPV1, 5-HT1A, adenosine-related signaling, and PPAR-gamma. Not all of those mechanisms are equally established in humans, but together they make one point unavoidable: cannabinoid effects often sit on a network, not a single receptor switch.

That network perspective also explains why intoxication is a bad master metric for public safety. A product can be less intoxicating than THC yet still produce concerning drug interactions, liver-enzyme effects, cardiovascular strain, panic reactions, or sedation. It can also be more intoxicating without being more predictable. The public often hears “weaker than THC” or “stronger than THC” as though that settles the issue. It does not. Those are usually statements about one salient phenotype, not a full toxicological profile.

The research pipeline is already moving beyond THC-equivalence. A 2025 Nasdaq release from MIRA Pharmaceuticals described preclinical data for MIRA-55 claiming a “differentiated mechanism of action” and anxiolytic activity relative to THC. Company press releases are weak evidence compared with peer-reviewed clinical data, so the claim should be handled cautiously. Still, the direction of travel is real: medicinal chemistry is trying to separate desired effects from central intoxication by changing target engagement. The same translational logic appears in a 2026 ScienceDaily report describing work on “a cannabis compound that relieves pain without the high.” Research-stage findings are not clinical proof, but they reinforce a central regulatory point. If beneficial effects can be split from intoxication, then harms can be split from intoxication too. A low-high product is not automatically a low-risk product.

Why novel cannabinoids demand target-level scrutiny

Novel cannabinoids deserve more scrutiny, not less, precisely because they are often introduced into commerce before their pharmacology is mapped in humans. The old shortcut was to ask whether a molecule binds CB1 or CB2. The better question is what else it does, and whether those actions become relevant at real doses after inhalation, oral ingestion, or metabolism.

For pain, TRP channels and sodium channels are obvious examples. David Julius and Ardem Patapoutian received the 2021 Nobel Prize in Physiology or Medicine for discoveries of receptors for temperature and touch, a reminder that somatosensory biology is built on targets that cannabinoids can influence outside the classical cannabinoid receptors. TRPV1 activation can contribute to analgesia through desensitization, but it can also produce irritation and is strongly concentration-dependent. A regulator looking only for CB1 activity will miss that entire risk-benefit axis.

For psychiatric safety, serotonin signaling matters. CBD has repeatedly been discussed as a 5-HT1A-linked anxiolytic candidate, but serotonin involvement can be indirect and context-dependent. That uncertainty is not a reason to ignore the target; it is a reason to study it carefully before products are normalized as harmless. The same goes for GPR55, sometimes floated as a “CB3” candidate despite ongoing debate. A contested target is still a target that can shape calcium signaling, excitability, and inflammatory responses.

For metabolic and inflammatory effects, intracellular targets such as PPAR-gamma complicate the picture further. Nuclear receptor signaling does not look like a fast intoxicant effect, yet it may matter for chronic exposure, adipose distribution, transcriptional changes, and interaction with other disease states. Public health messaging built around whether something “gets you high” misses those slower, quieter risks.

This is where regulation, toxicology, and consumer safety communication need molecular-target literacy. Not every in vitro hit will matter clinically. Species differences are real. Metabolites can dominate. But agencies should demand target panels, metabolite characterization, concentration-response data, and impairment-relevant human studies before assuming one new cannabinoid can be governed like another. The 2016 ACS Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands” reflects how drug discovery now works: structure-based design, selectivity engineering, and explicit attention to receptor-level differences. Regulation should stop pretending the market is simpler than the medicinal chemistry already knows it is.

Public health cannot afford receptor reductionism. “Cannabinoid” is a starting label. It is not a safety conclusion.

Drug discovery: designing cannabinoids and cannabinoid-inspired molecules for non-CB1/CB2 targets

Drug discovery around cannabinoids has moved far beyond the old question of whether a molecule is “CB1-active” or “CB2-active.” That simplification was always shaky, because many cannabinoid-related compounds are pharmacologically messy: they hit ion channels, GPCRs outside the canonical pair, intracellular nuclear receptors, transport processes, and metabolizing enzymes, often with different effects depending on concentration, tissue, and route of administration. For medicinal chemists, that mess is not just a problem. It is also an opportunity.

The central design goal is clear enough: keep analgesic, anti-inflammatory, or anxiolytic effects, while shrinking liabilities tied to strong CB1 activation in the brain. Those liabilities are not abstract. Sedation, cognitive impairment, intoxication, abuse potential, and dose-limiting psychiatric effects are exactly why “THC-like” is often a bad profile in a development program, even when THC itself shows useful pharmacology. The current regulatory climate reinforces that point. In 2025, HHS backed scheduling action by stating that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety,” a reminder that modified or enhanced intoxicants cannot be assumed to behave like familiar plant-derived compounds simply because they sit nearby on a marketing shelf. Target-level pharmacology matters.

Peripheral restriction, functional selectivity, and biased signaling

One route around central adverse effects is blunt but effective: keep the drug out of the brain. Peripheral restriction can be engineered by raising polar surface area, increasing hydrogen-bonding capacity, adjusting pKa, or making the molecule a substrate for efflux transporters at the blood-brain barrier. The idea is not unique to cannabinoid science, but it fits the field unusually well because pain signaling often begins in peripheral nociceptors, inflamed tissues, and dorsal root ganglia.

That is where non-CB1/CB2 targets become especially attractive. A 2025 Hebrew University report argued that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 sodium channels, two major drivers of nociceptive excitability. If that mechanism holds up across systems, it matters a great deal. NaV1.7 has long been treated as a premium pain target because human loss-of-function mutations in SCN9A can produce profound congenital insensitivity to pain. A cannabinoid scaffold that preserves sodium-channel modulation in the periphery while minimizing central CB1 signaling would not just be “less intoxicating THC.” It would be a different kind of analgesic.

TRP channels create a similar opening. The broader sensory biology here was recognized at the highest level when the 2021 Nobel Prize in Physiology or Medicine went to David Julius and Ardem Patapoutian for discoveries of receptors for temperature and touch. TRPV1, TRPA1, and related channels are deeply tied to nociception and inflammatory signaling, and several phytocannabinoids interact with them in ways that are concentration-sensitive and sometimes paradoxical: initial activation can be followed by desensitization, with the latter potentially contributing to analgesia. That makes medicinal chemistry harder, not easier. But it also means a compound does not need to be a clean on-off orthosteric CB receptor ligand to have therapeutic value.

Functional selectivity adds another layer. Even at CB1 or CB2 themselves, ligands can favor one signaling output over another, shifting the balance among G-protein pathways, beta-arrestin recruitment, receptor internalization, and downstream transcriptional programs. In plain terms, two molecules can both “bind CB1” and still behave very differently in living tissue. The 2016 Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands” reflects how far design strategy has shifted toward structure-based tuning rather than crude receptor labels. The same logic now extends beyond CB receptors: chemists want scaffolds whose shape, lipophilicity, and conformational constraints bias them toward a pain-relevant or anxiolytic mechanism while avoiding heavy central signaling baggage.

CBD is the standing proof that a cannabinoid-related drug can matter clinically without being explained by CB1/CB2 agonism. The FDA labeling for cannabidiol oral solution, updated in 2024, covers seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year and older. Whatever combination of TRPV1, 5-HT1A, GPR55-related, adenosinergic, intracellular, and network-level effects ultimately explains that efficacy, it is not a simple CB1 story. Drug hunters noticed.

MIRA-55 and the push for differentiated mechanisms

MIRA-55 is a useful case study, not because it settles anything, but because it shows how companies now frame cannabinoid programs. In a 2025 Nasdaq-carried press release, MIRA Pharmaceuticals said its candidate showed a “differentiated mechanism of action” and “anxiolytic activity relative to THC” in preclinical work. That phrasing tells you almost everything about current investor and regulatory signaling. Being cannabinoid-inspired is no longer enough. A company wants distance from plain THC mimicry, especially for indications like anxiety where central adverse effects can erase the benefit.

Still, skepticism is mandatory. “Differentiated mechanism” in a corporate release is a claim, not a conclusion. It may mean altered receptor engagement, changed tissue distribution, distinct metabolites, partial agonism, functional bias, off-target ion-channel effects, or simply a different behavioral profile in one animal assay. Without full pharmacology panels, concentration-response curves, metabolite identification, receptor occupancy data, and blinded replication, the phrase is more a hypothesis than a result.

That said, the strategy behind the claim is believable. If a compound can reduce anxiety-like behavior while lowering intoxication, memory disruption, or locomotor suppression relative to THC, the medicinal chemistry probably changed one or more of four things: brain penetration, intrinsic efficacy at CB1, engagement of non-CB targets such as 5-HT1A or TRP channels, or metabolic conversion into active species with a different target profile. Those are exactly the axes on which modern cannabinoid programs compete.

MIRA-55 also illustrates the target-deconvolution problem. Cannabinoid-like molecules are often “dirty” in the pharmacological sense. That is not a moral judgment; it is a mechanistic warning. If a preclinical anxiolytic signal appears, one cannot assume a single receptor explains it. Serotonin signaling may be direct or indirect. PPAR-gamma effects may require intracellular accumulation or metabolites. GPR55 can look important in one assay and marginal in another. An in vitro hit at 10 micromolar may be irrelevant if free brain concentrations never approach that level in vivo.

What a realistic cannabinoid pipeline looks like

A realistic pipeline is narrower and more disciplined than public rhetoric suggests. It is not a parade of “non-psychoactive cannabis compounds” rushing toward approval. It is a filter.

At the front end sit scaffold modification and triage: classical cannabinoids, nonclassical cannabinoids, endocannabinoid-inspired lipids, and unrelated chemotypes that mimic one useful feature of cannabinoid pharmacology without inheriting the whole package. Chemists alter side-chain length, ring constraints, stereochemistry, heteroatom placement, and metabolic soft spots, then test not just CB1 and CB2 but TRPV1, TRPA1, NaV channels, selected orphan GPCRs, and serotonin-relevant assays. Hits then face ADME work, unbound concentration analysis, and brain-to-plasma measurements. Many die there.

The programs that survive usually split into a few credible categories. One is peripherally restricted analgesics, where the dream is pain relief through sodium channels, TRP desensitization, inflammatory modulation, or peripheral cannabinoid signaling without substantial CNS exposure. Another is biased or low-efficacy CB1 ligands that aim to preserve therapeutic signaling while reducing intoxication. A third is mixed-mechanism compounds, often more realistic than single-target purism, where modest actions at several pain or anxiety nodes beat a “clean” but clinically weak ligand.

The translational hook that keeps this area alive is simple: separation of analgesia from the high appears possible, at least in research-stage systems. ScienceDaily’s 2026 summary of new work describing “a cannabis compound that relieves pain without the high” should be treated carefully, because headlines outrun data, but the concept fits the broader medicinal-chemistry direction. So does the sodium-channel work on THC. So do efforts to build selective ligands by docking and structure-guided design. The pattern is consistent even when individual claims need trimming.

What the pipeline probably does not look like is mass clinical success in the near term. Target promiscuity, metabolite complexity, species differences, and formulation effects keep breaking simple stories. But the field is no longer stuck asking whether cannabinoids are “really” about CB1 and CB2. Drug developers have already answered that question with their chemistry budgets. They are designing for the space beyond those receptors, because that is where the best chance of separating benefit from liability now sits.

Common misconceptions and unresolved controversies

The biggest mistake in public discussion of cannabinoids is receptor reductionism: the urge to force a messy pharmacology into one headline target. That habit was always shaky, and it is getting riskier as regulators and drug developers confront compounds that are no longer just “THC” or “CBD” in the simple, plant-derived sense. In 2025, HHS said that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” when backing DEA action on enhanced 7-OH products. Different drug class, same lesson: once chemists alter, enrich, or semi-synthesize an intoxicating scaffold, old assumptions about receptor action and safety can fail fast. Cannabis science has the same problem. A cannabinoid is not a magic key for one lock. It is usually a promiscuous ligand whose real-world effects depend on concentration, tissue exposure, metabolism, and which off-targets become relevant at those levels.

Is there really a CB3 receptor

No consensus CB3 receptor exists.

That answer sounds blunt because the evidence warrants it. Several receptors have been proposed over the years as “CB3” candidates, especially GPR55, sometimes GPR18, and occasionally other orphan GPCRs that respond in some assay systems to cannabinoid ligands or endocannabinoid-related lipids. But a proposed target is not an accepted receptor class. CB1 and CB2 earned their names through converging evidence: cloning, reproducible ligand pharmacology, tissue distribution, signaling, and broad replication. The putative CB3 candidates have never cleared that bar.

GPR55 is the usual suspect. It is expressed in the brain, immune cells, gut, and bone, and some cannabinoids do interact with it. CBD has often been described as a GPR55 antagonist in cell assays; certain synthetic cannabinoids show activity too. Yet the pharmacology is inconsistent across labs, ligands, and readouts. Some compounds look active in one signaling assay and quiet in another. Species differences complicate the picture. Endogenous ligands are debated. Most importantly, calling GPR55 “CB3” suggests a settled place inside the canonical cannabinoid receptor family that the field has not granted it.

This matters because labels can outrun evidence. Once a receptor gets a catchy nickname, the nickname starts doing explanatory work it has not earned. Pain? CB3. Anxiety? CB3. Bone effects? CB3. That is not pharmacology; it is branding. The more careful position is that GPR55, GPR18, GPR119, and related receptors are non-CB1/CB2 targets with varying degrees of evidence for modulation by cannabinoids or cannabinoid-like lipids. Some may matter a great deal in specific tissues. None has achieved consensus status as “the third cannabinoid receptor.”

Drug discovery has moved accordingly. Medicinal chemistry papers do not act as if one new receptor name will solve the system. The 2016 Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands” is a good marker of where the field actually is: structure-based design, receptor selectivity, scaffold engineering, and target-directed optimization, not mythology about a mysterious CB3 waiting to explain everything. Likewise, company claims about next-generation cannabinoid-inspired compounds now often emphasize differentiated mechanisms rather than simply stronger receptor agonism. MIRA Pharmaceuticals’ 2025 preclinical press release for MIRA-55 explicitly claimed a “differentiated mechanism of action” and anxiolytic activity relative to THC. That is promotional material, not settled science, but it reflects a real strategic shift: useful cannabinoid therapeutics may come from getting away from blunt CB1 intoxication, not from discovering one catch-all receptor.

Does CBD work mainly through serotonin

Also no, though serotonin signaling is part of the story.

CBD is frequently marketed in popular culture as if it were basically a natural 5-HT1A drug. That simplification survives because there is real evidence behind it. In preclinical studies, CBD has shown anxiolytic- and anti-stress-like effects that are reduced by 5-HT1A antagonists in some paradigms. Human experimental studies have also hinted that serotonergic mechanisms may contribute to acute anxiolytic effects under certain conditions. But “contributes to” is not “mainly works through.”

CBD is pharmacologically broad. It has low affinity for CB1 and CB2 compared with THC, yet that does not make it a single-target serotonin agent by default. Across the literature, plausible contributors include TRPV1, 5-HT1A, GPR55, adenosine signaling, PPAR-gamma, intracellular calcium handling, FAAH-related endocannabinoid tone in some contexts, and effects of metabolites that may not match the parent compound. Concentration matters here more than many explainers admit. A receptor effect seen in vitro at micromolar levels may not dominate in humans after a standard oral dose, where absorption is variable and first-pass metabolism is substantial.

The clinical record pushes against one-mechanism claims. The strongest FDA-recognized use of purified CBD is not anxiety at all but seizure disorders: the oral solution is indicated for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients 1 year and older. That approved use already tells you something. If CBD were “mainly serotonin,” its most reproducible therapeutic profile would be hard to square with what clinicians actually use it for. Serotonin may matter in anxiety-related settings, especially 5-HT1A-linked responses, but CBD’s human pharmacology does not collapse into a serotonin label.

Even within anxiety, the mechanism probably shifts with dose and context. TRPV1 is a good example. CBD can activate TRPV1, and TRP signaling is central enough to sensory biology that David Julius and Ardem Patapoutian received the 2021 Nobel Prize for discoveries of receptors for temperature and touch. Yet TRPV1 effects are not linear. Activation can be followed by desensitization; low and high doses can produce different behavioral outcomes. So when someone says “CBD works through serotonin,” the right response is: partly, sometimes, and probably not alone.

Can one target explain a whole-plant effect

No single target can explain a whole-plant cannabis effect, and trying to force one usually obscures more than it clarifies.

Whole-plant effects emerge from stacked variables. Start with composition: THC, CBD, minor cannabinoids such as CBG, CBC, THCV, acidic precursors, oxidation products, and metabolites each bring distinct target profiles. Add route of administration and the picture changes again. Inhaled cannabinoids reach the brain quickly; oral products undergo first-pass metabolism and generate different active species. U.S. law still defines hemp by a delta-9 THC threshold of “not more than 0.3 percent on a dry weight basis,” but that legal line says little about the pharmacology of everything else in the sample or what forms after metabolism.

Then add tissue specificity. A cannabinoid can affect central CB1, peripheral TRP channels, immune signaling, and nuclear receptors in parallel. The 2025 Hebrew University report that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 is a sharp example because it breaks the lazy equation “THC effect=CB1 effect.” If even THC has meaningful sodium-channel actions in pain pathways, the idea that a flower, extract, or edible has one master receptor becomes hard to defend. The 2026 research highlighted by ScienceDaily—a cannabis compound relieving pain without the high—points in the same direction, though it remains research-stage. Analgesia may be separable from central intoxication by exploiting peripheral restriction or non-CB1 targets. That is where the field is heading.

Expectancy and individual biology matter too. Prior experience, anxiety level, genetics, sex, liver enzyme activity, sleep, inflammation, and concurrent medications all shift what a given product feels like and what it does physiologically. Terpenes may contribute in some cases, but they should not be treated as magic directors of the entire effect. Their concentrations are often low, and human evidence is thinner than marketing language suggests.

The harder but more accurate view is this: cannabis effects are emergent. They arise from many modest interactions, not one slogan receptor. That makes the science less tidy. It also makes it more honest.

Practical interpretation for readers, clinicians, and researchers

The practical lesson from non-CB1/CB2 cannabinoid pharmacology is simple but demanding: mechanism claims should get harder scrutiny, not easier acceptance, once a paper invokes TRP channels, PPARs, GPR55, 5-HT1A, adenosine signaling, or NaV channels. Cannabinoids are often pharmacologically promiscuous molecules. That can be useful in drug discovery. It can also mislead readers into treating any receptor hit in a dish as an explanation for a clinical effect.

A good rule is to rank evidence by distance from the patient. A binding assay is the start, not the finish. Cell-signaling studies come next. Animal work can sharpen plausibility. Human experimental pharmacology matters more. Approved-drug evidence matters most, and even there the label may not settle the mechanism. Cannabidiol oral solution, for example, is FDA-approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients age 1 year and older, yet its therapeutic profile is not cleanly explained by CB1 or CB2 activation. That gap is exactly why claims about TRPV1, GPR55, 5-HT1A, and intracellular targets keep resurfacing.

How to read cannabinoid mechanism claims critically

Start with the species and system. Was the effect shown in human tissue, a rodent cell line, Xenopus oocytes, or overexpressed receptors in HEK293 cells? Those are not interchangeable. GPR55 is a prime example: one study may show CBD behaving as an antagonist in a recombinant system, while another context produces weak or variable signaling because receptor expression, endogenous lipids, and assay design differ. Calling that “the mechanism” is usually premature.

Then ask the concentration question. This is where many cannabinoid claims collapse. A paper may report TRPV1 activation, PPAR-gamma transactivation, or sodium-channel inhibition at micromolar concentrations. Fine. But does the human dose being discussed actually produce free tissue concentrations in that range? Oral cannabinoids face first-pass metabolism, extensive protein binding, and uneven tissue distribution. A target hit at 30 micromolar in vitro may be interesting chemistry and irrelevant bedside pharmacology. The reverse can also happen: local tissue accumulation, active metabolites, or lipid partitioning may make an intracellular target more plausible than plasma levels alone suggest. Either way, concentration is not a side issue. It is the issue.

Direct target measurement matters too. Did investigators actually block the effect with a selective antagonist, knock down the receptor, or measure channel current? Or did they infer the mechanism from similarity to prior literature? For TRP channels, especially TRPV1 and TRPA1, this matters because activation can be biphasic and desensitizing. A compound can first activate a channel and then reduce downstream responsiveness, which means “agonist” does not always map neatly onto “more pain” or “more heat sensation.” That is one reason the 2021 Nobel Prize to David Julius and Ardem Patapoutian, awarded “for their discoveries of receptors for temperature and touch,” is so relevant here: somatosensory signaling is mechanistically rich, and simplistic receptor labels often fail.

The NaV story shows what stronger evidence looks like. Hebrew University researchers reported in 2025 that THC inhibits peripheral nociceptors by targeting NaV1.7 and NaV1.8 nociceptive sodium channels. That claim is more informative than vague statements that THC “works outside CB1,” because it names pain-relevant channels already central to analgesic research. It also reframes an old assumption. Even a compound famous for CB1-mediated intoxication may have clinically relevant non-CB actions, especially in peripheral tissue.

Readers should also watch for competing explanations. Suppose a study links CBD to anxiolysis through 5-HT1A. Reasonable hypothesis. But was sedation ruled out? Was CB1 modulation indirect? Did the experiment distinguish receptor-level effects from changes in endocannabinoid tone, adenosine uptake, inflammatory signaling, or expectancy in human subjects? Multi-target drugs rarely announce which target is doing most of the work in any given model.

The current regulatory climate makes this skepticism more than academic. In 2025, HHS stated that “7-hydroxymitragynine (7-OH) poses an imminent hazard to public safety” when supporting scheduling action on enhanced 7-OH products. That is not a cannabis case, but the lesson carries over cleanly: regulators are increasingly distinguishing familiar plant constituents from enhanced, semi-synthetic, or otherwise modified intoxicants with different potency and safety profiles. Cannabinoid policy that treats all compounds as scaled versions of delta-9-THC is pharmacologically out of date.

Questions clinicians should ask about target relevance

Clinicians do not need to memorize every orphan GPCR to interpret cannabinoid claims well. They need a disciplined checklist.

First: was the effect shown in humans or only in cells and animals? A mouse inflammatory model can support plausibility for PPAR-gamma or TRPA1 involvement, but it does not establish patient benefit. Second: at what concentrations or doses? If a proposed target is engaged only at levels above what standard oral dosing reaches, that mechanism may not explain routine clinical outcomes. Third: was the target directly measured? Receptor occupancy, electrophysiology, antagonist reversal, or genetic disruption all count more than narrative inference.

Fourth: does the route of administration make the claim more or less believable? Inhalation, oral ingestion, transdermal delivery, and topical application create very different exposure profiles. A peripheral analgesic mechanism is more plausible for a topical or peripherally restricted compound than for a molecule that rapidly floods the brain. That distinction matters if the therapeutic goal is analgesia without intoxication.

Fifth: are there competing explanations tied to known adverse effects? If a patient reports less anxiety after a cannabinoid preparation, is that a 5-HT1A-mediated anxiolytic effect, reduced pain, nonspecific sedation, or expectancy? If inflammation markers move, is PPAR-gamma the likely driver, or did broader metabolic or immune changes occur upstream? Mechanism should not be inferred from symptom improvement alone.

For clinicians, minor cannabinoids deserve the same caution. CBC, CBG, THCV, and acidic cannabinoids are often discussed as if each comes with a stable signature target profile. The literature does not justify that confidence yet. Some are promising. None should be treated as pharmacologically settled simply because a brand name or social-media thread claims receptor specificity.

Where the field is likely headed next

The most credible near-term direction is peripheral analgesia. The translational appeal is obvious: separate pain relief from central intoxication. The 2026 ScienceDaily report describing work on “a cannabis compound that relieves pain without the high” should be read as a research-stage signal, not a finished clinical answer, but it captures where medicinal chemistry is aiming. The same is true of the 2025 Hebrew University NaV1.7/NaV1.8 work: pain biology is pushing cannabinoid science toward peripheral nerves, ion channels, and tissue-selective exposure.

Anti-inflammatory nuclear-receptor ligands are another strong lane. PPAR-gamma claims need better target-engagement data in humans, but the concept is plausible enough to justify serious development, especially where metabolic and inflammatory pathways intersect. Multi-target anxiolytics are also likely to remain active territory. MIRA Pharmaceuticals said in a 2025 Nasdaq release that its candidate MIRA-55 showed a “differentiated mechanism of action” and “anxiolytic activity relative to THC” in preclinical data. Because that is company-reported and preclinical, it should be treated cautiously. Still, it reflects a real trend: researchers are no longer satisfied with asking whether a candidate is “like THC” or “like CBD.” They want defined target profiles.

That same shift is visible in medicinal chemistry. The 2016 Journal of Medicinal Chemistry paper “Library Docking for Cannabinoid-2 Receptor Ligands” signaled a structure-based approach that has only grown since then: build ligands for specific targets, specific tissues, and specific signaling biases. Better-defined minor cannabinoids will likely emerge from this mindset, not from broad claims that every rare cannabinoid has a unique wellness niche.

The practical takeaway is blunt. When reading cannabinoid pharmacology, ask five questions every time: Was the effect shown in humans or only in cells? At what concentrations? Was the target directly measured? Does the dose reach that target in living tissue? Are there competing explanations? The future of cannabinoid science is not less specific pharmacology, but more.